Acyclic nucleoside derivatives
Patent Information
- Application Number
- MYPI1997000553
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 1996-02-16
- Filing Date
- 1997-02-14
- Publication Date
- 1997-08-16
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current acyclic nucleosides have modest pharmacokinetics, limiting their bioavailability, and existing prodrug approaches, such as ester derivatives, have only modestly improved oral bioavailability for herpes and retroviral infections.
Development of diester derivatives of H2G combining specific amino acid esters and fatty acid esters, which significantly enhance oral bioavailability compared to parent compounds and traditional fatty acid esters.
The mixed amino acid/fatty acid diester derivatives of H2G provide improved or comparable oral bioavailability to valine ester derivatives, effectively treating herpes and retroviral infections, including severe cases like shingles and infectious mononucleosis, with reduced duration and severity.
Abstract
Description
Acyclic Nucleoside DerivativesTechnical FieldThis invention relates to the field of antivirals and in particular to derivatives ofacyclic nucleosides useful against herpes and retroviral infections. The inventionprovides novel compounds, pharmaceutical compositions comprising thesecompounds, methods for the treatment or prophylaxis of viral infections employingthem, methods for their manufacture and novel intermediates.Background to the inventionThe practical utility of many acyclic nucleosides is limited by their relativelymodest pharmacokinetics, A number of prodrug approaches have been explored inan effort to improve the bioavailability of acyclic nucleosides in general. One ofthese approaches involves the preparation of ester derivatives, particularly aliphaticesters, of one or more of the hydroxy groups on the acyclic side chain.European patent EP165 289 describes the promising antiherpes agent9-[4-hydroxy-(2-hydroxymethyl)butyl]guanine, otherwise known as H2G.European patent EP 186 640 discloses 6-deoxy H2G. European patent EP 343 133discloses that these compounds, particularly the R-(-) enantiomer, are additionallyactive against retroviral infections such as HIV. Various derivatives of H2G, suchas phosphonates, aliphatic esters (for example, the diacetate and the dipropionate)and ethers of the hydroxy groups on the acyclic side chain are disclosed inEP 343 133. This patent also discloses methods for the preparation of thesederivatives comprising the condensation of the acyclic side chain to the N-9 positionof a typically 6-halogenated purine moiety or, alternatively, the imidazole ringclosure of a pyrimidine or furazano-[3,4-d] pyrimidine moeity or the pyrimidinering closure of an imidazole moiety, where the acyclic side chain is already presentin the precursor pyrimidine or imidazole moiety, respectively. In the broadest' * -.-v*"'-' c'dechain ispre-derivatised butindividual examples also show a one-step diacylation of H2G with acetic orproprionic anhydride and DMF,Hamden, et ah, J. Med. Chem. 32, 1738 (1989) investigated a number of short chainaliphatic esters of the acyclic nucleoside 9-[4-hydroxy-(3-hydroxymethyl)butyl]guanine, otherwise known as penciclovir, and its 6-deoxy analog. Famciclovir, amarketed antiviral agent, is the diacetyl derivative of 6-deoxy penciclovir.Benjamin, et al., Pharm. Res. 4 No. 2, 120 (1987) discloses short chain aliphaticesters of 9-[( 1,3-dihydroxy-2-propoxy)-methyl] guanine, otherwise known asganciclovir. The dipropionate ester is disclosed to be the preferred ester.Lake-Bakaar, et al., discloses in Antimicrob. Agents Chemother. 33 No. 1, 110-112(1989) diacetate and dipropionate derivatives of H2G and monoacetate and diacetatederivatives of 6-deoxy H2G. The diacetate and dipropionate derivatives of H2G arereported to result in only modest improvements in bioavailability relative to H2G.International patent application W094 / 24134, published October 27, 1994,discloses aliphatic ester prodrugs of the 6-deoxy N-7 analog of ganciclovir,including the di-pivaloyl, di-valeroyl, mono-valeroyl, mono-oleoyl and mono-stearoyl esters.International patent application W093 / 07163, published April 15, 1993 andInternational patent application W094 / 22887, published October 13, 1994, bothdisclose mono-ester derivatives of nucleoside analogs derived from mono-unsaturated C18 or C20 fatty acids. U.S. Patent No. 5,216,142, issued June 1, 1993,also discloses long chain fatty acid mono-ester derivatives of nucleoside analogs.A second approach to providing prodrugs of acyclic nucleosides involves thepreparation of amino acid esters of one or more of the hydroxy groups on the acyclicside chain European patent EP 99 493 discloses generally amino acid esters ofacyclovir and European pateni application EP 30S 065, published March 22, 1989.discloses the valine and isoJeucine csrers of acyclovir.European pateni application EP 375 329, published June 27, 1990, discloses aminoacid ester derivatives of ganciclovir, including the d;-valine, di-isoleucine, di-glycine and di-alanine ester derivatives. International patent applicationW095 / 09S55, published April 13, 1995, discloses amino acid ester derivatives ofpenciclovir, including the mono-valine and di-valine ester derivatives.DE 19526163, published February 1, 1996 and U.S. Patentno. 5,543.414 issuedAugust 6, 1 996 , disclose achiral amino acid esters of ganciclovir.European parent application EP 694 547, published January 31, 1996, discloses themono-L-vaime ester of ganciclovir and its preparation from di-valyl-ganciclovir.European patent application EP 654 473, published May 24, 1995, discloses variousbis amino acid ester derivatives of 9-[l\2,-bishydroxymethyJ)-cyclopropan-ryl]methyl guanine.International patent application W095 / 22330, published August 24, 1995, disclosesaliphatic esters, amino acid esiers and mixed acelatc / valinate esters of the acyclicnucleoside 9-[3f3-dihydroxymethyl-4-hydroxy-bui-l-yl]guanine. This referencediscloses that bioavailability is reduced when one of the valine esters of the irivalineester derivative is replaced with an acetate ester.Brief Description of the InventionWe have found that diestcr derivatives of H2G bearing specific combinations of anamino acid ester and a fatty acid ester are able to provide significantly improved oralbioavailability relaiive to the parent compound (H2G). In accordance with a firstaspect of the invention there is thus provided a compound of the formula Iwhere a) R, is -C(0)CH(CH(CH3)2)NH2 or-C(0)CH(CH(CH3)CH2CH3)NH2 and R2 is -C(0)C3-C21 saturated ormonounsaturated, optionally substituted alkyl; oris -C(0)C3-C21 saturated or monounsaturated, optionallysubstituted alkyl and ^ is -C{0)CH(CH(CH3)2)NH2 or-C(0)CH(CH(CHj)CH2CH3)NH2; andR3 is OH or H;and pharmaceutical^ acceptable salts thereofThe advantageous effect on oral bioavailability of the mixed fatty acid and aminoacid esters of the invention is particularly unexpected in comparison to the oralbioavailability of the corresponding fatty acid esters. Based on the results using aurinary recovery assay (Table 1 A) or a plasma drug assay (Table IB) of H2G fromrats, neither the mono or di-fatty acid esters of H2G provide any improvement inoral bioavailability relative to the parent compound H2G. Indeed the di-stearatederivative provided significantly lower bioavailability than the parent indicating thata stearate ester may be detrimental for improving oral bioavailability of H2G.Converting one or both of the hydroxyls in certain other acyclic nucleosideanalogues to the corresponding valine or di-valine ester has been reported toimprove bioavailability. Conversion of H2G to the coresponding mono- or di-valylester derivatives produced similar improvement in bioavailability relative to theparent compound. Given that fatty acid derivatives of H2G are shown to bedetrimental for improving bioavailability, it was unexpected that a mixed aminoacid / fatty acid diester derivative of H2G would provide improved or comparableoral bioavailability to that of the valine diester derivative of H2G, based on urinerecovery and plasma drug assays, respectively.Table IA* see Biological Example I below for detailsTABLE IB# see Biological Example 2 below for detailsThe invention also provides pharmaceutical compositions comprising thecompounds of Formula I and their pharmaceutical^ acceptable salts in conjunctionwith a pharmaceutic ally acceptable carrier or diluent. Further aspects of theinvention include the compounds of Formula I and their pharmaceutical^acceptable salts for use in therapy and the use of these compounds and salts in thepreparation of a medicament for the treatment or prophylaxis of viral infection inhumans or animals.The compounds of the invention are Dotent antivirals, especially against herpesinfections, such as those caused by Varicella zoster virus, Herpes simplex virustypes 1 & 2, Epstein-Barr virus, Herpes type 6 (HHV-6) and type 8 (HHV-8). Thecompounds are particularly useful against Varicella zoster virus infections such asshingles in the elderly including post herpetic neuralgia or chicken pox in the youngwhere the duration and severity of the disease can be reduced by several days.Epstein Barr virus infections amenable to treatment with the compounds includeinfectious mononucleosis / glandular fever which has previously not been treatablebut which can cause many months of scholastic incapacity amongst adolescents.The compounds of the invention are also active against certain retroviral infections,notably S1V, HTV-1 and HIV-2, and against infections where a transactivating virusis indicated.Accordingly a further aspect of the invention provides a method for the prophylaxisor treatment of a viral infection in humans or animals comprising the administrationof an effective amount of a compound of Formula I or its phaimaceuticallyacceptable salt to the human or animal.Advantageously group R3 is hydroxy or its tautomer =0 so that the base portion ofthe compounds of the invention is the naturally occuring guanine, for instance in theevent that the side chain is cleaved in vivo. Alternatively, R3 may be hydrogen thusdefining the generally more soluble 6-deoxy derivative which can be oxidised invivo (e.g. by xanthine oxidase) to the guanine form.The compound of formula I may be present in racemic form, that is a mixture of the2R and 2S isomers. Preferably, however, the compound of formula I has at least70%, preferably at least 90% R form, for example greater than 95%. Most preferablythe compound of formula I is enantiomerically pure R form.Preferably the amino acid of group R, / R2 is derived from an L-amino acid.Preferably the fauy acid of group Rj / Rj has in total an even number of carbonatoms. in particular, decanoyj (Cui), teury] (Ci:), myrisioyJ (Cn). palmitoyl (Ci6),siearoyl (CiK) or eicosanoyl {C2U). Other useful R, / R: groups include buiyryl,hexanoy], octanoyl or behenoyi (C;:). Further useful Rj / R: croups include thosederived from myristoleic, mynstelaidic. palmiioJeic, paJmiielaidic, n6-octadecenoictoleic, elaidic. gandoic, erucic or brassidic acids. Monounsaturated fatty acid esterstypically have ihc double bond in the trans configuration, preferably in the co-6, c>9or to-11 position, dependent upon their length. Preferably the Rj / R; group is derivedfrom a fatty acid which comprises a C9 to Cn saturated, or n:9 (alternatively denotedw-9, ie where the double bond is between carbons 9 and 10 counted from the methylterminus) monounsaturated, alkyl.The saturated or unsaturated fatty acid or Rj / R: may optionally be substituted withup io five similar or differem substituents independently selected from the groupconsisting of such as hydroxy, Ci-C* alkyl, C\~C6 alkoxy, CrC6 alkoxy Cj-Cfc alkyl,Ci-Cfi alkanoyl, amino, halo, cyano, aiido, oao, mercapto and niiro, and the like.Most preferred compounds of the formula I are those where R i is-C(0)CH<CH(CH3)2)NH2 or -C(0)CH(CH<CH3)CH2CH3)NH2 and Ra is -C(0)C9-CJ7saruraied alky!.The term "lower aikyP as used herein refers to straight or branched chain alkylradicals containing from 1 io 7 carbon atoms including, but not limited to, methyl,ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl t-butyl, n-pentyl.1-methylbutyl, 2,2-dimethylbutyl, 2-mcthyIptntyl, 2.2-dimeihylpropyl, n-hexyl andthe like.The term "N-protecting group" or "N-protected" as used herein refers to thosegroups intended to protect the N-terminus of an amino acid or peptide or to protccian amino group against undesirable reactions during synthetic procedures.Commonly used N-proreciing groups are disclosed in Greene, "Protective Groups inOrganic Synthesis" (John Wiley & Sons. New York, i9S 1), which is herebyincorporated by reference. N-proiectinj; groups include acv] groups such zs formvj,incorporated by reference. N-protecting groups include acyl groups such as formyl,acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl,trifluoracetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, a-chlorobutyryl,benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and the like; sulfonylgroups such as benzenesulfonyl, p-toluenesulfonyl, and the like, carbamate forminggroups such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl,p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl,2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl,3,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl,2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl,l-(p-biphenylyl)-I-methylethoxycarbonyl, a,a-dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butoxycarbonyl,diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl,methoxycarbonyl, allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyI,phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl,cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl,phenylthiocarbonyl, and the like; alkyl gropus such as benzyl, triphenylmethyl,benzyloxymethyl and the like; and silyl groups such as trimethylsilyl and the like.Favoured N-protecting groups include formyl, acetyl, benzoyl, pivaloyl,t-butylacetyl, phenylsulfonyl, benzyl, t-butoxycarbonyl (BOC) andbenzyloxycarbonyl (Cbz).The term "activated ester derivative" as used herein refers to acid halides such asacid chlorides, and activated esters including, but not limited to, formic and aceticacid derived anhydrides, anhydrides derived from alkoxycarbonyl halides such asisobutyloxycarbonylchloride and the like, N-hydroxysuccinimide derived esters,N-hydroxyphthalimide derived esters, N-hydroxybenzotriazole derived esters,N-hydroxy-5-norbomene-2,3-dicarboxamide derived esters, 2,4,5-trichIorophenylderived esters and the like.Preferred compounds of formula I include:(R)-9-[2-(butyryloxymethy!)-4-(L-isoleucyloxy)butyl]guanine,(R)-9-[2-(4-acetylbutyryloxymethyl)-4-(L-isoleucyloxy)butyl]guanine,(R)-9-[2-(hexanoyloxymethyl)-4-(L-isoleucyloxy)butyl]guanine,(R)-9-[4-(L-isoleucyloxy)-2-(octanoyIoxymethyl)butyl]guanine,(R)-9-[4-(L-isoleucyloxy)-2-(decanoyloxymethyl)butyl]guanine,(R)-9-(4-(L-isoleucyloxy)-2-(dodecanoyloxymethyl)butyl]guanine,(R)-9-[4-(L-isoleucyloxy)-2-(tetradecanoyloxymethyl)butyl]guanine,(R)-9-[4~(L-i so leucyloxy)-2-(hexadecanoyloxymethyl)butyl] guanine,(R)-9-[4-(L-isoleucyloxy)-2-(octadecanoyIoxymethyl)butyl]guanine,(R)-9-[2-(eicosanoyloxymethyi)-4-(L-isoleucyloxy)butyl]guanine,(R)-9-[2-(docosanoyloxymethyl)-4-(L-isoIeucyIoxy)butyl]guanine,(R)-944-(L-isoleucyloxy)-2-((9-tetradecenoyI)oxymethyl)butyl]guanine,(R)-9-[2-((9-hexadecenoyl)oxymethyl)-4-(L-isoleucyloxy)butyl]guanine,(R)-9-[4-(L-isoleucyloxy)-2-((6-octadecenoyI)oxymethyl)butyl]guanineJ(R)-9-[4-(L-isoleucyloxy)-2-((9-octadecenoyI)oxymethyl)-butyl]guanine,(R)-9-[2-(( 11 -eicosanoyI)-oxymethyl)-4-(L-isoleucyloxy)butyl]guanine,(R)-9-[2-((13-docosenoyl)-oxymethyl)-4-(L-isoleucyloxy)butyl]guanine,(R)-2-amino-9-[2-(butyryloxymethyl)-4-(L-isoIeucyloxy)butyl]purine,R)-2-amino-9-[2-(4-acetylbutyryloxymethyl)-4-(L-isoleucyloxy)butyl]purine,(R)-2-amino-9-[2-(hexanoyloxyraethyl)-4-(L-isoleucyIoxy)butyl]purine,(R)-2-amino-9-[4-(L-isoleucyloxy)-2-(octanoyloxymethyl)butyl]purine,(R)-2-amino-9-[4-(L-isoleucyloxy)-2-(decanoyloxymethyl)butyl]purine,(R)-2-amino-9-[4-(L-isoIeucyloxy)-2-(dodecanoyloxymethyl)butyl]purine,(R)-2-amino-9-[4-(L-isoIeucyloxy)-2-(tetradecanoyIoxymethyl)butyl]purine,(R)-2-amino-9-[4-(L-isoIeucyloxy)-2>(hexadecanoyloxymethyl)butyI]purine,(R)-2-amino-9-[4-(L-isoleucyloxy)-2-(octadecanoyloxymethyl)butyl]purine)(R)-2-amino-9-[4-(L-isoleucyloxy)-2-(eicosanoyloxymethyl)butyl]purine,(R)-2-amino-9-[2-(eicosanoyloxymethyl)-4-{L-isoleucyloxy)butyl]purine,(R)-2-amino-9-[2-(docosanoyloxymethyl)-4-(L-isoleucyIoxy)butyl]purine,(R)-2-amino-9-[4-(L-isoIeucyloxy)-2-((9-tetradecenoyl)oxymethyl)butyl]purine,(R)-2-amino-9-[2-((9-hexadecenoyl)oxvmethyI)-4-(L-isoIeucyloxy)butyl]purine,(R)-2-amino-9-[4-(L-isoleucyloxy)-2-((6-octadecenoyl)oxymethyl)butyl]purine,(R)-2-amino-9-[4-(L-isoIeucyloxy)-2-((9-octadecenoyl)oxymethyl)butyl]purine,(R)-2-amino-9-[2-(( 11 -eicosanoyl)oxymethyl)-4-{L-isoleucyloxy)butyl]purine, or(R)-2-amino-9-[2-((13-docosenoyl)oxymethyl)-4-(L-isoleucyloxy)butyl]purine,and their pharmaceutic ally accepable salts.Further preferred compounds include:(R)-9-[2-(butyryloxymethyI)-4-(L-vaIyloxy)butyl]guanine,(R)-9-[2-(4-acetylbutyryIoxymethyl)-4-(L-valyloxy)butyl]guanine,(R)-9-[2-(hexanoyloxymethyl)-4-(L-valyloxy)butyl]guanine,(R)-9-[2-(octanoyIoxymethyl)-4-(L-valyloxy)butyl]guanine,(R)-9-[2>(decanoyloxymethyl)-4-(L-valyloxy)butyI]guanine,(R)-9-[2-(dodecanoyloxymethyl)-4-(L-valyIoxy)butyl]guanine,i(R)-9-[2-(tetradecanoyloxymethyl-4-(L-valyloxy)butyl]guanine,(R)-9-[2-hexadecanoyloxymethyl)-4-(L-valyloxy)butyI]guanine,(R)-9-[2-(octadecanoyloxymethyl)-4-(L-valyloxy)butyI]guanine,(R)-9-[2-(eicosanoyloxymethyl)-4-(L-valyloxy)butyl]guanine,(R)-9-[2-(eicosanoyloxymethyl)-4-(L-valyloxy)butyl]guanine,(R)-9-[2-(docosanoyloxymethyl)-4-(L-vaIyloxy)butyl]guanine,(R)-9-[2-((9-tetradecenoyl)oxymethyl)-4-(L-valyloxy)butyI]guanine,(R)-9-[2-((9-hexadecenoyl)oxymethyl)-4-(L-valyloxy)butyl]guanine,(R)-9-[2-((6-octadecenoyl)oxymethyl)-4-(L-valyloxy)butyl]guanine,(R)-9-[2-((9-octadecenoyl)oxymethyl)-4-(L-valyloxy)-butyl]guanine,(R)-9-[2-((l l-eicosanoyl)oxymethyI)-4-(L-valyloxy)butyl]guanine,(R)-9-[2-(( 13-docosenoyl)oxymethyl)-4-(L-valyloxy)butyl]guanine,(R)-2-amino-9-[2-(butyryloxymethyl)-4-(L-valyloxy)butyI]purine,(R)-2-amino-9-[2-(4-acetylbutyryloxymethyl)-4-(L-vaIyloxy)butyl]purine,(R)-2-amino-9-[2-(hexanoyloxymethyI)-4-(L-valyloxy)butyl]purine,(R)-2-amino-9-[2-<octanoyloxymethyl)-4-(L-valyloxy)butyl]purine,(R)-2-amino-9-[2-(decanoyIoxymethyl)-4-(L-valyloxy)butyl]purine,(R)-2-arnino-9-[2-(dodecanoyloxymethyl)-4-(L-valyloxy)butyI]purinp.(R)-2-amino-9-[2-(tetradecanoyIoxymethyJ)-4-(L-valy!oxy)butyl]purine,(R)-2-amino-9-[2-(hexadecanoyloxymethyI)-4-(L-valyloxy)butyl]purineT(R)-2-amino-9-[2-(octadecanoyIoxymethyl)-4-(L-valyloxy)-butyl]purine,(R)-2-amino-9-[2-(eicosanoyIoxymethyl)-4-(L-valyloxy)butyl]purine,(R)-2-amino-9-[2-(docosanoyloxymethyl)-4-(L-valyloxy)butyI]purine,(R)-2-amino-9-[2-((9-tetradecenoyl)oxymethyl)-4-(L-valyloxy)butyl]purine,(R)-2-amino-9~[2-((9-hexadecenoyl)oxymethyl)-4-(L-valyloxy)butyi]purine,(R)-2-amino-9-[2-((6-octadecenoyI)oxymethyl)-4-(L-valyIoxy)butyl]purine,(R)-2-amino-9-[2-((9-octadecenoyi)oxymethyI)-4-(L-valyloxy)-butyl]purine,(R)-2-amino-9-[2-((ll-eicosenoyI)-oxymethyl)-4-(L-valyloxy)butyl]purine, or(R)-2-amino-9-[2-((13-docosenoyI)-oxymethyl)-4-(L-valyloxy)butyl]purine;and their pharmaceutical^ acceptable salts.Other preferred compounds of formula I include:(R)-9-[4-(butyryloxy)-2-(L-valyloxymethyl)butyl]guanine,(R)-9-[4-(4-acetyIbutyryloxy)-2-(L-valy!oxymethyl)butyl]guanine,(R)-9-[4-(hexanoyloxy)-2-(L-vaIyloxymethyl)butyl]guanine,(R)-9-[4-(octanoyloxy)-2-(L-valyloxymethyl)butyl]guanine,(R)-9-[4-(decanoyloxy)-2-(L-valyIoxymethyl)butyl]guanine,(R)-9-[4~(dodecanoyloxy)-2-(L-valyloxymethyl)butyl]guanine,(R)-9-[4-(tetradecanoyloxy)-2-(L-vaIyIoxymethyl)butyl]guanine,(R)-9-[4-hexadecanoyloxy)-2-(L-valyloxymethyl)butyI]guanine,(R)-9-[4-(octadecanoyloxy)>2-(L-valyIoxymethyl)butyl]guanine,(R)-9-[4-(eicosanoyloxy)-2-(L-valyloxymethyl)butyl]guanine,(R)-9-[4-(docosanoyIoxy)-2-(L-valyloxymethyl)butyl]guanine,(R)-9-[4-((9-tetradecenoyl)oxy)-2-(L-valyloxymethyl)butyl]guanine,(R)-9-[4-((9-hexadecenoyl)oxy)-2-(L-valyIoxymethyl)butyl]guanine,(R)-9-[4-((6-octadecenoyl)oxy)-2-(L-valyloxymethyl)butyl]guanine,(R)-9-[4-((9-octadecenoyl)oxy)-2-(L-valyloxymethyl)-butyl]guanine,(R)-9-[4-((l l-eicosenoyl)oxy)-2-(L-valyloxymethyl)butyI]guanine,(R)-9-[4-((13-docosenoyl)-oxy)-2~(L-valyloxyi"nethyl)buty]]guanine,(R)-2-ainino-9-[4-(butyryIoxy)-2-(L-valyloxymethyl)butyl]purine,(R)-2-amino-9-[4-(4-acetylbmyryloxy)-2-(L-valyloxymetbyI)butyl]piirine)(R)-2-amino-9-[4-(bexa]ioyloxy)-2-(L-valyloxymetbyI)buty!]puririe,(R)-2-amino-9-[4-(octanoyloxy)-2-(L-va)y]oxymethyi)butyl]punne,(R)-2-amino-9-[4-(decanoyloxy)-2-(L-valyIoxymethyI)buty ^purine,(R)-2-amino-9-[4-(dodecanoyloxy)-2-(L-va)yIoxymethyl)butyl]purine,(R)-2-amino-9-[4-(tetradecanoyloxy)-2-(L-valyloxymethyl)buty)]purineJ(R)-2-amino-9-[4-(hexadecanoyloxy)-2-(L-va]yloxymethyl)butyl]purine,(R)-2-amino-9-[4-(octadecanoyloxy)-2-(L-valyloxymethyl)-butyl]purine,(R)-2-ammo-9-[4-(eicosanoyloxy)-2-(L-valyloxyrnethyl)bmyl]purine,(R)-2-amino-9-[4-(docosanoyloxy)-2-(L-va]y]oxyrnethyl)butyl]purine,(R)-2-amino-9-[4-((9-tetradecenoyl)oxy)-2-(L-valy]oxymethyl)butyl]purine,(R)-2-ainino-9-[4-((9-hexadecenoyl)oxy)-2-(L-valyloxymetbyl)buty]]purine,(R)-2-airiino-9-[4-((6-octadecenoyl)oxy>2-(L-va]yloxyiTiethyl)buty]]purine,(R)-2-amino-9-[4-((9-octadecenoyl)oxy)-2-(L-vaIyIoxymethyl)butyl]purine,......- - L ■ V.V.-- ----------' J • f---J J — — .J. J J J Ij^UUIlV,(R)-2-amino-9- [2-(( 13-docosenoyl)oxymethyl)-2-(L-valyloxy)butyl]purine3 orand their pharmaceutical^ acceptable salts.The compounds of formula I can form salts which form an additional aspect of theinvention. Appropriate pharmaceutically acceptable salts of the compounds offormula I include salts of organic acids, especially carboxylic acids, including butnot limited to acetate, trifluoroacetate, lactate, gluconate, citrate, tartrate, maleate,malate, pantothenate, isethionate, adipate, alginate, aspartate, benzoate, butyrate,digluconate, cyclopentanate, glucoheptanate, glycerophosphate, oxalate, beptanoate.hexanoate, fumarate, nicotinate, palmoate, pectinate, 3-phenylpropionate, picrate,pivalate, proprionate, tartrate, lactobionate, pivolate, camphorate, undecanoate andsuccinate, organic sulphonic acids such as methanesulphonaie. elhanesulphonate,2-hydroxyethane sulphonate, camphorsulphonate, 2-napthalenesulphonate,ben2enesuIphonate. p-chlorobenzenesulphonate and p-toluenesulphonate; andinorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate,bisulphate, hemisulphate, thiocyanate, persulphate, phosphoric and sulphonic acids.Hydrochloric acid salts are convenient.The compounds of Formula 1 may be isolated as the hydrate. The compounds of theinvention may be isolated in crystal form, preferably homogenous crystals, and thusan additional aspect of the invention provides the compounds of Formula I insubstantially pure crystalline form, comprising >70%, preferably >90%homogeneous crystalline material for example >95% homogeneous crystallinematerial.The compounds of the invention are particularly suited to oral administration, butmay also be administered rectally, vaginally, nasally, topically, transdermally orparenterally, for instance intramuscularly, intravenously or epiduraliy. Thecompounds may be administered alone, for instance in a capsule, but will generallybe administered in conjunction with a pharmaceutical^ acceptable carrier or diluent.The invention extends to methods for preparing a pharmaceutical compositioncomprising bringing a compound of Formula I or its pharmaceutical^ acceptablesalt in conjunction or association with a pharmaceutical^ acceptable carrier orvehicle.Oral formulations are conveniently prepared in unit dosage form, such as capsulesor tablets, employing conventional carriers or binders such as magnesium stearate,chalk, starch, lactose, wax, gum or gelatin. Liposomes or synthetic or naturalpolymers such as HPMC or PVP may be used to afford a sustained releaseformulation. Alternatively the formulation may be presented as a nasal or eye drop,syrup, gel or cream comprising a solution, suspension, emulsion, oil-in-water orwater-in-oil preparation in conventional vehicles such as water, saline, ethanol,vegetable oil or glycerine, optionally with flavourant and / or preservative and / oremulsifier.The compounds of the invention may be administered at a daily dose generally inthe range 0.1 to 200 mg / kg / day, advantageously, 0.5 to 100 mg / kg / day, morepreferably 10 to 50mg / kg / day, such as 10 to 25 mg / kg / day. A typical dosage rate fora normal adult will be around 50 to 500 mg, for example 300 mg, once or twice perday for herpes infections and 2 to 10 times this dosage for HTV infections.As is prudent in antiviral therapy, the compounds of the invention can beadministered in combination with other antiviral agents, such as acyclovir,valcyclovir, penciclovir, famciclovir, ganciclovir and its prodrugs, cidofovir,foscamet and the like for herpes indications and AZT, ddl, ddC, d4T, 3TC,foscamet, ritonavir, indinavir, saquinavir, delaviridine, Vertex VX 478, AgouronAG 1343 and the like for retroviral indications.The compounds of the invention can be prepared de novo or by esterification of theH2G parent compound which is prepared, for example, by the synthesismethodology disclosed in European Patent EP 343 133, which is incorporatedherein by reference.A typical reaction scheme for the preparation of H2G is depicted overleaf:The condensation in step 1 is typically carried out with a base catalyst such asNaOH or Na^Oj in a solvent such as DMF. Step 2 involves a reduction which canbe performed with LiBH / tetrahydrofuran in a solvent such as t-BuOH. Thesubstitution in step 3 of the chlorine with an amino group can be performed underpressure with ammonia. Step 4 employs adenosine deaminase which can beconveniently immobilized on a solid support. Cooling the reaction mixture allowsunreacted isomeric precursor to remain in solution thereby enhancing purity.Starting materials for compounds of the invention in which R3 is hydrogenmay be prepared as shown in European Patent HP 186 640, the contents ofwhich are incorporated herein by reference. These starting materials may beacylated as described for H2G below, optionally after protecting the purine 2-amino group with a conventional N-protecting group as defined above,especially BOC (t-BuO-CO-), Z (BnO-CO-) or Ph3C-.The compounds of the invention may be prepared from H2G as describedbelow in Schemes A and B.A. Direct acvlation methodScheme A depicts the preparation of compounds in which R, is derived fromthe amino acid and R2 is derived from the fatty acid, but the converse schemeis applicable to compounds where R, is derived from the fatty acid and R2 isderived from the amino acid ester. In the variant specifically depicted inscheme A above, G is guanine or 6-deoxyguanine, PG is an optional N-protecting group or hydrogen, R,* is the valine or isoleucine side chain andR2* is the fatty acid chain. H2G is depicted above as a starting material butthis of course may be optionally protected at R3 or the 2 position of the purinewith conventional N-protecting groups (not shown). The H2G (derivative)reacts in the first step with an activated R, a-amino acid derivative, as furtherdescribed below, in a solvent such as dimethylformamide or pyridine, to givea monoacylated product. The R, a-amino acid may be suitably N-protectedwith N-BOC or N-CBz or the like. Under controlled conditions, the firstacylation can be made to predominantly take place at the side chain 4-hydroxygroup on the side chain of H2G. These controlled conditions can be achieved,especially of the acylating agent, by lowering the temperature or by the choiceof solvent. The reaction can be followed by TLC to monitor the controlledconditions.After purification, the R, monoacylated compounds are further acylated on theside chain 2-CH2OH group with the appropriate activated fatty acid derivativeto give diacylated products using similar procedures as for the firstesterification step. The diester products are subsequently subjected to aconventional deprotection treatment using for example trifluoroacetic acid,HCl(aq) / dioxane or hydrogenation in the presence of catalyst to give thedesired compound of Formula I. The compound may be in salt formdepending on the deprotection conditions.The activated R, / R2 derivative used in the various acylations maycomprise e.g. the acid halide, acid anhydride, activated acid ester or the acid inthe presence of coupling reagent, for example dicyclohexylcarbodiimide,where "acid" in each case represents the corresponding R, / R2 amino acid orthe R, / R: fatty acid. Representative activated acid derivatives include the acidchloride, formic and acetic acid derived mixed anhydrides, anhydrides derivedfrom alkoxycarbonyl halides such as isobutyloxycarbonylchloride and thelike, N-hydroxysuccinamide derived esters, N-hydroxyphthalimide derivedesters, N-hydroxy-5-norbomene-2,3-dicarboxamide derived esters,2,4,5-trichlorophenol derived esters and the like.3. Via protection of the side chain 4-hydroxy group:wherein G, PG, R,* and R2* are as described for scheme A.Scheme B has been exemplified with reference to the preparation of acompound where Kx is derived from an amino acid and R2 is derived from thefatty acid ester, but a converse scheme will be applicable to compounds whereR2 is derived from the amino acid and R, is derived from the fatty acid. Thisscheme relies on regioselective protection of the H2G side chain 4-hydroxygroup with a bulky protecting group. In scheme B above this is depicted ast-butyldiphenylsilyl, but other regioselective protecting groups such as trityl,9-(9-phenyi)xanthenyI, I,l-bis(4-methylphenyl)-r-pyrenylmethyl may alsobe appropriate. The resulting product is acylated at the side chain2-hydroxymethyl group usin^ analogous reagents and procedures as describedin scheme A above, but wherein the activated acid derivative is the R2 fattyacid, for example, myristic, stearic, oleic, elaidic acid chloride and the like.The thus monoacylated compounds are subjected to appropriate deprotectiontreatment to remove the side chain 4-hydroxy protecting group which can bedone in a highly selective manner with such reagents, depending on theregioselective protecting group, as HF / pyridine and the like and manipulationof the reaction conditions, viz reagent concentration, speed of addition,temperature and solvent etc, as elaborated above. The then free side chain4-hydroxy group is acylated with the activated a-amino acid in a similar wayas described in scheme A above.Additional techniques for introducing the amino acid ester of R, / R2, forinstance in schemes A, B, C or D herein include the 2-oxa-4-aza-cycloalkane-1,3-dione method described in international patent application no. WO94 / 29311.Additional techniques for introducing the fatty acid ester of R, / R2, for instancein schemes A, B, C or D herein include the enzymatic route described inPreparative Biotransformations 1.11.8 (Ed S M Roberts, J Wiley and Son,NY, 1995) with a lipase such as SP 435 immobilized Candida antarcticus(Novo Nordisk), porcine pancreatic lipase or Candida rugosa lipase.Enzymatic acylation is especially convenient where it is desired to avoid N-protection and deprotection steps on the other acyl group or the purine 2-amine.An alternative route to compounds of Formula I in which R3 is hydrogen is to6-activate the correponding guanine compound of Formula I (wherein theamino acid ester moiety of R, / R2 is optionally protected with conventionalN-protecting groups such as BOC) with an activating group such as halo. Thethus activated 6-purine is subsequently reduced to purine, for instance with apalladium catalyst and deprotected to the desired 6-deoxy H2G di-ester.A further aspect of the invention thus provides a method for the preparation of thecompounds of formula I comprisinga) optionally N-protecting the purine 2 and / or 6 positions of a compound offormula I wherein R[ and R2 are each hydrogen;b) regioselectively acylating the compound of Formula 1 at the side chain4-hydroxy group with eitheri) an optionally N-protected valine or isoleucine group,ii) an optionally substituted, saturated or monounsaturated C3-Cj,COOH derivative, oriii) a regioselective protecting group;c) acylating at the side chain 2-hydroxymethyl group withi) an optionally N-protected valine or isoleucine derivative, orii) an optionally substituted, saturated or monounsaturated C3-C2lCOOH derivative;d) replacing the regioselective protecting group at Rt, if present, withi) an optionally N-protected valine or isoleucine derivative; orii) an optionally substituted, saturated or monounsaturated C3-C2ICOOH derivative; ande) deprotecting the resulting compound as necessary.Schemes A and B above employ selective acylation to stepwise add the amino acid andfatty acid esters. An alternative process for the preparation of the compounds of formula Istarts with a diacylated H2G derivative, wherein both the acyl groups are the same, andemploys selective removal of one of the acyl groups to obtain a monoacyl intermediatewhich is then acylated with the second, differing, acyl group in the same manner asSchemes A and B above.Accordingly a further aspect of the invention provides a method for the preparation of acompound of the formula I, as defined above, which method comprisesA) the monodeacylation of a diacylated compound corresponding to formula Iwherein R, and R2 are both a valyl or isoleucyl ester (which is optionallyN-protected) or are R, and R2 are both -C(=0)C3-C2i saturated or monounsaturaLed,optionally substituted alkyl; andB) acylating the thus liberated side chain 4-hydroxy or side chain2-hydroxymethyl group with the corresponding valyl, isoleucyl or -C(=0)C3-C2lsaturated or monounsaturated, optionally substituted alkyl; andC) deprotecting as necessary.This alternative process has the advantage that the preparation of the diacylated H2Gderivative is facile and requires little or no purification steps. Selective removal of oneonly of the acyl groups of a diacylated H2G derivative can be achieved by manipulatingthe reaction conditions, in particular the temperature, rate of reactant addition and choiceofbase.Compounds amenable to this alternative synthesis route are thus of the formula:where R, and R2 are valyl or isoleucyl (which are optionally N-protected) or a-C(=0)C3-C2I saturated or monounsaturated, optionally substituted alkyl; and R3 isOH or H.For ease of synthesis in this alternative route, it is preferred that Rj and R2 are bothinitially identical and are most preferably the same amino acid ester. Such a di-amino acid ester will generally be N-protected during its preparation and may beused directly in this condition in the selective deacylation step. Alternatively, suchan N-protected di-aminoacylated H2G derivative may be deprotected and optionallyreprotected, as described below. The unprotected di-aminoacyl H2G derivative thuscomprises one of the following compounds:(R)-9-[2-(L-isoleucyloxymethyl)-4-(L-isoleucyloxy)butyl]gu?r<ine,(R)-9-[2-(L-valyloxymethyl)-4-(L-valyloxy)butyl]guanine,(R)-2-amino-9-[4-(L-isoleucy1oxy)-2-(L-isoleucyloxymethyl)butyl]purine, and(R)-2-amino-9-[4-(L-valyloxy)-2-(L-valyloxymethyl)butyl]purine.These unprotected H2G diacylated derivatives can be directly subject to selectivedeacylation of one of the acyl groups (typically the side chain 4-position acyl)followed by enzymatic acylation of the liberated 4-hydroxy as described above.Alternatively, the unprotected H2G diacylated derivative can be re-protected andthen subjected to the selective deacylation, followed in turn by conventionalacylation with the fatty acid ester, as described in Schemes A and B. Conveniently,such a reprotection step is done with a different N-protecting group, havingproperties appropriate to the subsequent acylation. For example, it is convenient toemploy a lipophilic N-protecting group, such as Fmoc when preparing a di-aminoacid H2G derivative, as the lipophilic nature of the protecting group assists withseparation of the acylated products. On the other hand, the lipophilic nature of Fmocis of less utility when conducting an acylation with a fatty acid, and thus it isconvenient to reprotect a diacylated H2G with an alternative N-protecting groupsuch as BOC.It will also be apparent that the preparation of the compounds of formula I can commencewith the novel monoacylated intermediates of step b i), ii) or iii) in the above defined firstmethod aspect of the invention. These compounds are thus of the formula:where one of R, and R2 isi) -C(0)CH(CH(CH3)2)NH2 or -C(0)CH(CH(CH3)CH2CH3)NH2ii) a -C(=0)C3-C2. saturated or monounsaturated, optionally substitutedalkyl, oriii) a regioselective protecting group;the other of R, and R2 is hydrogen; andRj is OH or H;Useful compounds thus include:(R)-9-[2-hydroxymethyl-4-(t-butyldiphenylsilyl)butyl]guanine,(R)-9-[2-hydroxymethyl-4-(trityloxy)butyl]guanine,(R)-9-[2-hydroxymethyl-4-(9-(9-phenyl)xanthenyloxy)butyl]guanine,(R)-9-[2-hydroxymethyl-4-( 1,1 -bis(4-methylphenyl)-1pyrenylmethyloxy)butyl] guanine,(R)-9-[2-hydroxymethyl-4-(decanoyloxy)butyl]guanine,(R)-9-[2-hydroxymethyl)-4-(dodecanoyloxy)butyl]guanine,(R)-9-[2-hydroxymethyl-4-(tetradecanoyloxy)butyl]guanine,(R)-9-[2-hydroxymethyl)-4-(hexadecanoyloxy)butyl]guanine,(R)-9-[2-hydroxymethyl-4-(octadecanoyloxy)butyl]guanine,(R)-9-[2-hydroxymethyl)-4-(eicosanoyloxy)butyl]guanine,(R)-9-[2-hydroxymethyl-4-(docosanoyloxy)butyl]guanine,(R)-9-[4-hydroxy-2-(decanoyloxymethyl)butyl]guanine,(R)-9-[4-hydroxy-2-(dodecanoyloxymethyl) butyl]guanine,(R)-9-[4-hydroxy-2-(tetradecanoyloxymethyl)butyl]guanine,(R)-9-[4-hydroxy-2-(hexadecanoyloxymethyl)butyl]guanine,(R)-9-[4-hydroxy-2-(octadecanoyloxymethyl)butyl]guanine,(R)-9-[4-hydroxy-2-(eicosanoyloxymethyl)butyl]guanine,(R)-9-[4-hydroxy-2-(docosanoyloxymethyl)butyl]guanine,(R)-9-[2-hydroxymethyl-4-(L-valyloxy)butyl]guanine,(R)-9-[2-hydroxymethyl)-4-(L-isoleucyloxy)butyl]guanine,(R)-9-[4-hydroxy-2-(L-isoleucyloxymethyl)butyl]guanine,(R)-9-[4-hydroxy-2-(L-valyloxymethyl) butyl]guanine.(R)-2-amino-9-[2-hydroxymethyl-4-(L-valyloxy)butyl]purine,(R)-2-amino-9-[2-hydroxymethyl)-4-(L-isoleucyloxy)butyl]purine,(R)-2-amino-9-[4-hydroxy-2-(L-isoleucyloxymethyl)butyl]purine, and(R)-2-amino-9-[4-hydroxy-2-(L-valyloxymethyI)butyl]purine.Regioselectively protected, sidechain 4-hydroxy intermediates from step c) of theabove described first method aspect of the invention are also novel compounds.Useful compounds thus include:(R)-9-[2-decanoyloxymethyl-4-(t-butyldiphenylsilyl)butyl]guanine>(R)-9-[2-dodecanoyloxymethyl-4-(t-butyldiphenylsilyl)butyl]guanine,(R)-9-[2-tetradecanoyloxymethyl-4-(t-butyldiphenylsilyl)butyl]guanine,(R)-9-[2-hexadecanoyloxymethyl-4-(t-butyldiphenylchlorosilane)butyl]guanine,(R)-9-[2-octadecanoyloxymethyl-4-(t-butyldiphenylsilyl)butyl]guanine,(R)-9-[2-eicosanoyloxymethyI-4-(t-butyldipheny Is ilyl)butyl] guanine,(R)-9"[2-docosanoyloxymethyl-4-(t-butyldiphenylsilyl)butyl]guanine,An alternative process for the preparation of compounds of the invention of the formula Iwherein R3 is -OH is shown in Scheme C.SCHEME CReferring to Scheme C, malonate 1 (R4 and R5 are lower alkyl or benzyl or the like) isalkylated by reaction with from about 0.5 to about 2.0 molar equivalents of acetal 2 (1*6and R7 are lower alkyl or benzyl and the like or R^ and R7 taken together are -CH2CH2- or-CH2CH2CH2- or -CH2CH2CH2CH2-and X! is a leaving group (for example, CI, Br or I, ora sulfonate such as methanesulfonate, triflate, p-toluenesulfonate, benzenesulfonate andthe like)) in the presence of from about 0.5 to about 2.0 molar equivalents of a base (forexample, potassium t-butoxide or sodium ethoxide orNaH or KH and the like) in an inertsolvent (for example, DMF or THF or dioxane or dioxolane or N-methylpyrrolidone andthe like) at a temperature of from about -40°C to about 190°C to provide alkylatedmalonate 1.Reduction of 2 with from about 0.5 to about 4.0 molar equivalents of an ester to alcoholreducing agent (for example, LiBH4 or Ca(BH4)2 or NaBH„ or LiAlH4 and the like) in aninert solvent (for example, THF or methyl t-butyl ether or t-BuOH and the like) at atemperature of from about -20°C to about 100°C provides diol 4- Enzymatic esterificationof 4 by reaction with from about 1.0 to about 20.0 molar equivalents of a vinyl ester 5 (R-8is C3-C21 saturated or monounsaturated, optionally substituted alkyl) in the presence of alipase (for example, Lipase PS-30 or Lipase PPL or Lipase CCL and the like) or aphospholipase (for example phospholipase D and the like) provides the desiredstereoisomer of ester This reaction can be carried out in the absence of solvent or in thepresence of an inert solvent (for example, methyl t-butyl ether or toluene or hexane and thelike). The reaction is carried out at a temperature of from about -20°C to about 80°C.The alcohol substituent of £ is converted to a leaving group (for example, a halogen or asulfonate) by reaction with a halogenating agent (for example NBS / P(Ph)3 or NCS / P(Ph)3or POCI3 or NCS / P(Ph)3 / Nal in acetone and like) in an inert solvent (for example,methylene chloride or toluene or ethylacetate and the like) or by reaction with from about0.8 molar equivalents to about 2.0 molar equivalents of a sulfonyl halide (for example,benzenesulfonylchloride, toluenesulfonylchloride or methane sulfonylchloride and thelike) in the presence of from about 1.0 to about 4.0 molar equivalents of a base (forexample, triethylamine or potassium carbonate or pyridine or dimethyl am inopyridine orelhyldiisopropylamine and the like) in an inert solvent (for example methylene chloride ortoluene or ethylacetate or pyridine or methyl t-butyl ether and the like) at a temperature offrom about -25°C to about 100°C to provide ester 2. (X2 is a halogen or sulfonate leavinggroup).Reaction of 7 with from about 0.9 to about 2.0 molar equivalents of 2-amino-4-chloropurine £ in the presence of from about 1.0 to about 6.0 molar equivalents of a base(for example, potassium carbonate or NaH or KH or NaOH or KOH or lithiumdiisopropylamide and the like) in an inert solvent (for example, DMF or THF oracetonitrile or N-methylpyrrolidone or ethanol and the like) at a temperature of from about-25 °C to about 140°C provides substituted purineAlternatively Mitsunobu coupling (for example P(Ph)3 / diethyl azidocarboxylate) ofalcohol £ with 2-amino-4-chloropurine £ provides 2-Reaction of 2 with from about 2.0 to about 20 molar equivalents of an alcohol R9OH (R9is an alcohol protecting group such as benzyl and the like) in the presence of from about1.0 to about 6.0 molar equivalents of a base (for example, potassium t-butoxide orpotassium carbonate or NaH or KH or lithium diisopropylamide and the like) in an inertsolvent (for example, THF or DMF and the like) at a temperature of from about -25°C toabout 150°C provides alcohol JJ}.Removal of the alcohol protecting group R9 of 1Q (for example, by catalytichydrogenation in an inert solvent such as ethanol or benzyl alcohol or methanol or THFand the like in the presence of an hydrogenation catalyst such as Pd / C or Pd(OH)2 and thelike) provides substitued guanine H.Esterification of ii by reaction with a) from about 0.8 to about 2.0 molar equivalents ofR10COOH and a coupling agent (for example DCC / DMAP) and the like in an inert solvent(for example THF or DMF and the like) or b) from about 0.8 to about 2.0 molarequivalents of an activated derivative of RiqCOOH (for example, the acid chloride orN-hydroxysuccinimide ester or Rl0C(O)OC(O)R,0 and the like) in the presence of fromabout 0 to about 3.0 molar equivalents of a base (for example, pyridine or triethylamine orethyldiisopropylamine or DBU or potassium carbonate and the like) in an inert solvent (forexample, methylene chloride or THF or pyridine or acetonitrile or DMF and the like) at atemperature of from about -25°C to about 100°C provides ester 12-The acetal substituent of 12 is deprotected and the resulting aldehyde is reduced by firstreacting 12 with from about 0.1 to about 10.0 molar equivalents of an acid (for example,triflic acid or HCI or acetic acid or sulfuric acid and the like) in an inert solvent (forexample, THF / H2O or methylene ch!oride / H20 or ethyIacetate / H20 or ethanol / H20 ormethanol / H20 and the like) at a temperature of from about -25 °C to about 100°C. To thecrude reaction mixture is added from about 0.1 to about 10.0 molar equivalents of a base(for example, sodium bicarbonate or potassium carbonate or triethylamine or pyridine orKOH and the like), additional inert solvent (for example, THF and or methylene chlorideor ethylacetate or methyl t-butyl ether or isopropoanol and the like) and from about 0.3 toabout 5.0 molar equivalents of an aldehyde reducing agent (for example, sodiumborohydride or RaNi / H2 and the like) at a temperature of from about -25 °C to about100°C to provide alcohol 11.Reaction of 12 with from about 0.8 to about 3.0 molar equivalents of N-protected aminoacid P|NHCH(R| j)COOH or an activated derivative thereof (Pj is an N-protecting groupand K[\ is isopropyl or isobutyl) in an inert solvent (for example, THF or dioxane ordioxolane or DMF or methylene chloride and the like) at a temperature of from about 25°Cto about 100°C provides alcohol 14. N-deprotection of 14 provides the compound of theinvention of formula I wherein R3 is -OH.Alternatively compound 12 can be reacted with the symmetrical anhydride derived fromP,NHCH(Rn)COOH (i.e.P,NHCH(Rn)C(0)0-C(0)CH(Rn)NHP,) to provide 1 whereinR3 is OH.Another alternative process for the preparation of compounds wherein R3 is -OH is shownin Scheme D.SCHEME DMa)on2ie 1 (R. und R.s are. lower alky] or benzyl and the like) is alkylated with from about0.5 to about 2.0 molar equivalents of eiher 15 wherein X| is a leaving group (for exampleCI. Br or I, or a sulfonate such as methane sulfonate, inflate, p>to!uenesu)fonate,benzenesulfonate and the like) and R,3 is -CH(Ph)2l -C(Ph)3 or -5i(t-Bu)(Me): and the like(Ph = phenyl) in the presence of from 3bout 0.5 10 about 2.0 molar equivalents of a base(for example potassium t-butoxide or sodium eihoxiae or NaH or KH and the like) in aninert solvem (for example DMF or THF or dioxane or dioxolane or N-meiby)pyrrolidinone and the like) at a temperature of from about -40°C to about 190°C to providealkylated malonate 16.Reduction of J6 with from about 0.5 to about 4.0 molar equivalents of an ester to alcoholreducing agent (for example LiBHj or Ca(BHi): or NaBH* or LiAlH4 and the like) in aninert solvent (for example THF or methyl t-butyl ether cr.ethanol or t-butanol and the like)at a lemperature of from about -20°C to about ]00°C provides dio! 17. Enzymaticesierifjcation of 1? by reaction with from about 1.0 to about 20.0 molar equivalents of 0vinyl ester 5 (Rs is C3-CH saturated or monounsaturated, optionally substituted alkyl) inthe presence of a lipase (for example, Lipase PS-30 or Lipase PPL or Lipase CCL and thelike) or a phospholipase (for example phospholipase D and the like) provides the desiredstereoisomer of ester 18. The reaction can be carried out in the absence of solvent or in thepresence of an inert solvent (for example methyl t-butyl ether or toluene or hexane or thelike). The reaction is carried out at a temperature of from about -20°C 10 about 80eC.The alcohol substituent of J_8 is converted to a leaving group (for example a halogen orsulfonate) by reaction with a hologenating agent (for example NBS / P(Ph)3 or NCS / P(Ph)}or POCl3 or NCS / P(Ph)3 / Nal in acetone and the like) in an inert solvent (for examplemethylene chloride or toluene or ethylacetaie 2nd the like) or by reaction with from about0.8 mola: equivalents to about 2.0 molar equivalents of a sulfony] halidc (for examplebenzenesulfonylchloride, toluenesulfonylchloride or methane sulfonvlchloride and thelike) in the presence of from about 1.0 to about 4.0 molar equivalents of a base (forexample triethylamine or potassium carbonate or pyridine and the like) at atemperature of from about -25°C to about 100°C to provide ester 15. <X3 is ahalogen or sulfonate leaving group).Reaction of 12 with from about 0.9 to about 2.0 molar equivalents of 2-amino-4-chloropurine & in the presence of from about 1.0 to about 6.0 molar equivalents of a base(for example potassium carbonate or NaH or KH or NaOH or KOH or lithiumdiisopropylamide and the like) in an inert solvent (for example DMF or THF oracetonitrile or N-methylpyrrolidone or ethanol and the like) at a temperature of from about-25°C to about 140°C provides substituted purine 2Q.Alternatively, Mitsunobu coupling (for example, P(PH)3 / diethyl azidocarboxylate) ofalcohol IS with 2-amino-4-chloropurine £ provides 2Q.Reaction of 2Q with from about 2.0 to about 20.0 molar equivalents of an alcohol R^OH(R^ is an alcohol protecting group such as benzyl and the like) in the presence of fromabout 1.0 to about 6.0 molar equivalents of a base (for example, potassium t-butoxide orpotassium carbonate or NaH or KH or lithium diisopropylamide and the like in an inertsolvent (for example, THF or DMF and the like) at a temperature of from about -25°C toabout 150°C provides alcohol 21.Removal of the alcohol protecting group R, of 21 (for example by catalytic hydrogenationin an inert solvent such as ethanol or benzyl alcohol or methanol or THF and the like in thepresence of an hydrogenation catalyst such as Pd / C or Pd(OH)2 and the like) providessubstituted guanine 22-The ether substituted of 21 is deprotected by reaction with a) a reducing agent (forexample, HC02H and Pd / C and the like) wherein R12 is -CH(Ph)2 or -C(Ph)3, or b) adesilylating agent (for example Bu4NF and the like) wherein R,2 is -Si(t-Bu)(Me)2 and thelike to provide 13.Alcohol 12 can be converted to 1 as outlined in scheme C.An additional alternative involves enzymatic esterification of alcohol 4 or 12 with thevinyl ester CH2=CH-OC(O)R10 (i.e. R8 = Rl0 in Schemes C and D) to directly incorporateinto 6 or the desired carboxylic acid ester of the final product I. This allows theelimination of the ester hydrolysis and reesterification involved in going from 9 to 12 orfrom 2Q to 21-The processes of Schemes C and D are characterized by the fact that each ofthe hydroxyl groups of the acyclic side chain is differentiated by the use ofdifferent hydroxy protecting groups or precursor groups. This allows theselective acylation of each of the hydroxy groups with either an amino acid ora fatty acid group.Schemes C and D have been illustrated and described with reference toembodiments of the invention wherein R, is derived from an amino acid andR2 is derived from a fatty acid. However, it will be apparent that respectiveconverse schemes will apply to compounds where R, is derived from a fattyacid and R2 is derived from an amino acid.Detailed Description of the InventionThe invention will now be illustrated by way of example only with reference to thefollowing non-limiting Examples, comparative examples and the accompanyingFigures, in which:Figure 1 depicts plasma H2G levels as a function of time in cynomolgusmonkeys administered with a compound of the invention or with analternative prodrug derivative of H2G, as further explained in BiologicalExample 3; andFigure 2 depicts survival as a function of time for Herpes simplex infectedmice administered with various doses of a compound of the invention or aprior art antiviral, as further explained in Biological Example 4.EXAMPLE 1fRV9-[2-fStearoyloxvmethvn-4-(L-valyloxy)butvl]guanineThis example illustrates the application of preparation scheme A.a) (R)-9-[4-(N-tert-Butoxycarbonyl-L-valyloxy)-2-(hydroxymethyl)butyl]guanine.H2G (5 g, 19.7 mmol) was dissolved in DMF (300 ml) under heating and wascooled to room temperature before addition of N-f-Boc-L-valine (5.58 g, 25.7mmol), DMAP (0.314 g, 2.57 mmol) and DCC (6.52 g, 31.6 mmol). The mixturewas stirred at room temperature for 24 h and was then filtered. The product waschromatographed on silica gel and eluted with CH2Cl2 / MeOH to give 2.4 g of thedesired intermediate product.'H-NMR (250 MHz, DMSO-< / 6): 5 0.95 (d, 6H), 1.47 (s, 9H), 1.5-1.8 (m, 2H), 1.96-2.20 (m, 2H), 3.40 (m, 2H), 3.91 (t, 1H), 4.05 (m, 2H), 4.21 (t, 2H), 4.89 (t, 1H), 6.6(br s, 2H), 7.27 (d, 1H), 7.75 (s, 1H), 10.7 (br s, 1H).b) (R)-9-[4-(N-tert-Butoxycarbonyl-L-valyloxy)-2-(stearoyloxymethyl)butyl] guanineThe product from step a) (185 mg, 0.41 mmol) was dissolved in pyridine (5 ml), thesolution was cooled in an ice bath and stearoyl chloride (179 fil, 0.531 mmol) wasadded. The solution was kept in the ice bath for 2 h, then at room temperature for 1h. It was then evaporated and chromatographed on silica gel. It was eluted withdichloromethane / methanol to give 143 mg of the desired intermediate product.c) (R)-9-[2-(Stearoyloxymethyl)-4-(L-valyloxy)butyl]guanine.The product from step b) (138 mg, 0.192 mmol) was cooled in an ice bath andtrifluoroacetic acid (5 ml) was added. The solution was kept in the ice bath for 45minutes and was then evaporated to give an oil. Water (0.5 to 1 ml) was added andevaporated twice. The residue was once more dissolved in water (5 ml), filtered andfreeze-dried to give 148 mg of the desired product as the bistrifluoracetate salt.'H NMR (250 MHz, DMSO-rf6): 0.97 (t, 3H), 1.05 (dd, 6H), 1.34 (br s, 28 H), 1.59(m, 2H), 1.80 (m, 2H), 2.25 (m, 1H), 2.36 (t, 2H), 2.50 (m, 1H), 3.98-4.18 (m, 5H),4.35 (t, 2H), 6.6 (br s, 2H), 8.0 (br s, 1H), 8.4 (br s, 3H), 10.9 (br s, 1H).EXAMPLE 2rRV9-[2-rMyristoyloxymethy1)-4-(,L-valyloxv^butyl]guanineThe titled compound was obtained as the bistrifluoracetate salt in a manneranalogous to Example 1 using myristoyl chloride instead of stearoyl chloride instep b).]H NMR (250 MHz, DMSO-J6): 8 0.97 (t, 3H), 1.05 (dd, 6H), 1.34 (br s, 20H), 1.57(m, 2H), 1.78 (m, 2H), 2.24 (m, 1H), 2.35 (t, 2H), 2.51 (m, 1H), 3.97-4.20 (m, 5H),4.36 (t, 2H), 6.8 (br s, 2H), 8.2 (br s, 1H), 8.5 (br s, 3H), 11.1 (brs, 1H).EXAMPLE 3(RV9-[2-(Q1eoy1oxymethylM-(L-valyloxy)butyl] guanineThe titled compound was obtained as the bistrifluoroacetyl salt in a manneranalogous to Example 1 using oleoyl chloride instead of stearoyl chloride in step b).'H NMR (250 MHz, DMSO-< / 6): 0.96 (t, 3H), 1.05 (dd, 6H), 1.35 (br s, 20H), 1.59(m, 2H), 1.76 (m, 2H), 2.09 (m, 4H), 2.24 (m, 1H), 2.35 (t, 2H), 2.50 (m, 1H), 3.97-4.17 (m, 5H), 4.35 (t, 2H), 5.43 (t, 2H), 6.7 (br s, 2H), 8.0 (br s, 1H), 8.5 (br s, 3H),11.1 (brs, 1H).EXAMPLE 4(RV9-[2-fButyryloxymethylV4-(L-valyloxy>lbutyl]guanmea) (R)-9-[4-(N-tert-Butoxycarbonyl-L-valyloxy)-2-(butyryloxymethyl)butyl]guanineDCC (110 mg, 0.53 mmol) was dissolved in dichloromethane (10 ml) and butyricacid (82 mg, 0.93 mmol) was added. After 4 hours at room temperature the mixturewas filtered and ibe filtrate was evaporaied. The residue was dissolved in pyridine(5 mJ) and (R)-9-[4-(N-ien-Butoxycaibonyl-L-valyloxy)-2-hydroxymeihylbutvl]guanine (200 mg, 0.44 mmol) (Example 1. step a) was added. The mixture wasstirred for 120 hours at room temperature. According to TLC the reaction wasincomplete and more anhydride was made using the procedure above. Thisanhydride was added and the mixture was stirred for an additional 20 hours. Thereaction mixture was evaporated and chromatographed first on silica gel and then onaluminium oxide, in both cases eluled with dichloromeibane / methanol to give79 mg of the intermediate product.b) (R>9-[2-(Butyryloxymethy])-4~(L-valyloxy)butyl]guanineThe intermediate product of step a was deprotected in a manner analogous toExample 1, step c to give 84 mg of the desired product as the bistrifluoroacetatesalt.JHNMR (250 MHz, D20): 5 0.88 (t, 3H). 1.06(dd,6H), 1.53 (m. 2H), 1.93 (q. 2H),2.25 (t, 2H), 2.36 (m, IH), 2.60 fm, IH), 4.06 (d, IH), 4.14-4.30 (m, 2H), 4.43(m, 4H)r 8.99 (br s, IH).EXAMPLE 5rRV9-I2-('Pecanovloxvmethvr)-4-fL-va)vloxv'ibutvll guanineThe titled compound was obtained 2s ibe bistrifluoroaceiate salt in a manneranalogous to Example 1 using decanoyl chloride instead of stearoyl chloride instep b.'H NMR (250 MHz, D^O): 6 0.90 (m, 3H), 1.01 (d, 6H), 1.28 (brs, )2H), 1.5 (m,2H). 1.8 (m, 2H), 2.3 (m. 3H), 2.5 (m, IH), 4.0-4.4 (m, 7H), 8.1 (brs. IH).EXAMPLE 6(R)-9-[2-DocosanoylQxymethyl-4-(L-valytoxy)butyl1guanineThe titled compound was obtained as the bistrifluoroacetate salt in a manneranalogous to Example 1 but using in step b the DMAP / DCC conditions of Example1, step a) in conjunction with docosanoic acid in place of the N-f-Boc-L-valine anda mixture of DMF and dichloromethane as solvent.'H NMR (250 MHz, DMSCW6): 6 0.97 (t, 3H), 1.05 (dd, 6H), 1.34 (br s, 36 H),1.58 (m, 2H), 1.77 (m, 2H), 2.24 (m, 1H), 2.35 (t, 2H), 2.50 (m, 1H), 3.97-4.17 (m,5H), 4.35 (t, 2H), 6.7 (br s, 2H), 8.1 (br s, IH), 8.4 (br s, 3H), 11.0 (br s, 1H).EXAMPLE 7R-9-[4-(L-IsoleucyloxyV2-(stearoyloxymethyl)butyl] guanineThis example illustrates the application of preparative scheme B.a) ( R)-9-[2-hydroxymethyl 4-(t-butyldiphenylsilyloxy) butyl]guanineH2G (2g, 8 mmole) was coevaporated with dry DMF two times and was thensuspended in dry DMF (120 ml) and pyridine (1 ml). To the suspension wasadded dropwise t-butyldiphenylchlorosilane (2.1 ml, 8.2 mmole) indichloromethane (20 ml) at 0 °C over a period of 30 min. The reaction mixturebecame a clear solution at the completion of the dropwise addition. Thereaction continued at 0 °C for two hours and was then kept at 4 °C overnight.Methanol (5 ml) was added to the reaction. After 20 min at room temperature,the reaction mixture was evaporated to a small volume, poured into aqueoussodium hydrogen carbonate solution and extracted with dichloromethane twotimes. The organic phase was dried over sodium sulphate and evaporated invacuo. The product was isolated by silica gel column chromatography using amethanol / dichloromethane system with a stepwise increasing MeOHconcentration . The product was eluted with 7% MeOH in CH2C12 to yield1.89 g.b) (R)-9-[2-(Stearoyloxymethy])-4-(t-butyldiphenylsilyloxy)butyl]guanine(R)-9-[2-Hydroxymethyl 4-(t-butyldiphenylsilyloxy)butyl]guanine (2.31 g,5 mmole) was coevaporated with dry pyridine twice and dissolved in pyridine(20 ml). To the solution was slowly added dropwise stearoyl chloride (1.86ml, 5.5 mmole, technical grade) in dichloromethane (2 ml) at -5 °C. Thereaction was kept at the same temperature for 1 hr and then at 5 °C for 2 hr.The reaction was monitored by TLC. Additional stearoyl chloride (0.29 ml) at- 5° C was added due to incompletion of reaction. After 30 min at 5 °C,methanol (3 ml) was added and the reaction mixture stirred for 20 min. It wasthen poured into aqueous sodium hydrogen carbonate solution, and extractedwith dichloromethane. The organic phase was dried and the product purifiedby silica ge column chromatography with stepwise increasing MeOH, elutingwith 3.5 % MeOH in CH2C12 (Yield 2.7 g).c) (R)-9-[(4-Hydroxy-2-(stearoyloxymethyl)butyl]guanine(R)-9-[2-(StearoyIoxymethyl)-4-(t-butyidiphenylsiIyloxy)butyl]guanine (2.7 g,3.56 mmole) was dissolved in dry THF (30 ml) and hydrogen fluoride-pyridine(1.5 ml) added to the solution. The reaction was kept at 4°C overnight andmonitored by TLC. The reaction reached about 80 % conversion. Additional HF-pyridine was added (0.75 ml). After 4 hr, TLC showed that the starting material haddisappeared. The reaction mixture was concentrated in vacuo without raising thetemperature and more pyridine (5 ml) was added and evaporated again. The productwas isolated by silica gel column chromatography. (Yield 1.26 g).d) (R)-9- [4-(N-BOC-L-isoIeucyloxy)-2-(stearoyloxymethyl)butyl]guanine(R)-9-[4-Hydroxy-2-(stearoyIoxymethyI)butyl] guanine (135 mg, 0.26 mmole) andN-BOC-L-isoleucine (180 mg, 0.78 mmole) were coevaporated with dry DMF twiceand dissolved in the same solvent (3.5 ml). To the solution was added1,3-dicyclohexylcarbodiimide (160 mg, 0.78 mmole) and 4-dimethylaminopyridine(4.8 mg, 0.039 mmole). After reaction for 18 hours, the reaction mixture was^ " ^ rv'te and worked up in a conventional manner The product wasisolated by silica gel column chromatography, eluting at 5 % MeOH in CH:Ck(Yield 160 mg)e) (^^-[^-(L-jsoleucyloxyJO^stearoyloxymerhy^-butyllguanine(R)-9_[4.( N-BOC-L-isoleucyloxy)-2-(siearoyloxymethyl)butyI]guanine (150 mg,0.205 rnmole) from step d) was treated with trifluoroacetic acid (3 ml) at 0°C for 20min. The solution was evaporaied in vacuo. The residue was coevaporatcd withtoluene twice and kept under vacuum for several hours. The residue was dissolvedin MeOH (2 ml) and evaporated to give the tri fl uo race tai e sail as a glass-likeproducr (Yield 191 mg).H1 NMR (DMS0-46 + D20): 6 8.35 (s.lH. base), 4.21 (t, 2H. K-4). 4.10 (d, 2H)3.96 (d,2H), 3.90 (df IH, isoleucine), 2.48 (m, IHt H-2). 2.15 (2H, stearoyl), 1.85(m, IH. isoleucine), ].68 (m,2H)r 1.48 (m, 4H). 1.68 (m. 28H).0.81 (m, 9H).EXAMPLE 8(RV9-f2-rDecanovloxvmethvlV4-r L-isoleucvloxv')butvllsfuanineThe title compound was obtained as the bis-tri fluoro acetate salt in a manneranalogous to Example 7 using decanoyl chloride instead of stearoyl chloride in stepb).!HNMR (DMSO-t / 6): 5 11.1 (s, 1H.NH), 8.35 (s, br, 3H), 8.28 (s. IH, base), 6.75(s, 2H.'NHa ), 4.23 {t. 2H), 4.07 (d, 2H), 4.05 (m, 3H), 2.4 (m, IH), 2.21 (t, 2H),1.83 (m, IH), 1.66 (m. 2H), 1.45 (m. 2H). 1.39 (m. 2H), 1.22 (s, 12H }, 0.84(m, 9H).EXAMPLE 9fRV9-f4-(L-]soleucvioxy)-3-fmvnstovlo>:vmeihvMbuivn guanineThe title compound was obtained as the bis-trifluoroacetate salt in a manneranalogous to Example 3 using n-BOC-l-isoleucine instead of N-BOC-valine in stepa) and myristoyl chloride in siep b).lH-NMR CDMSO-^6): 5 10.99(5,1H). 8.34 (br s. 3H) 8.15 (s, JH ), 6.67 ( br s. 2H),4.23 (t, 2H), 4.05 (d, 2H), 3.97 (m. 3H), 2.48 (m, 1H), 2.20 (t. 2H), 1.S5 (m, 1H),1.65 (m, 2H)r 1.41 (m,4H)? 1.23 (s.20H),0.85 (m, 9H).EXAMPLE 10(RI^-n'^-Aceivlbutvrvloxvmethvl^-rL-valvloxv^butvnguanine_Tht titled compound was obtained as the bistrifluoroacetate salt in a manneranalogous to Example 1 but using in step b) the DCODMAP conditions of Example1. siep a) in conjunction with 4-acetylbutyric acid instead of stearyl chloride.]H-NMR (250 MHz, DMSO* / «): 6 1.05 (dd, 6H). 1.77 (m, 4H). 2.19 (s, 3H)'. 2.24(m, 1H), 2.36 ft, 2H), 2.44*2.60 (m, 3H), 3.95-4.20 (m, 5H). 4.36 (m, 2H), 6.8 (br s,2H), 8.3 (br s, IH)t 8.5 (br s, 3H), 11.1 (br s. 1H).EXAMPLE 11fRV9-f2-Dodccanovloxvm&thvM-(L-valvloxv)butvfl guanineThe titled compound was obtained as the bisiriflouToacttatt salt in 2 manneranalogous to Example 1 using dodecanoyl chloride instead of siearovl chloride instep b).EXAMPLE 12(RV9'f2'Palmiiovloxvmethvl-^-fL-vaIvloxv)butvllguanineThe tilled compound was obtained as the bistrifiouroacetate salt in a manneranalogous to Example 1 using palmitoyl chloride instead of stearoyl chloride in stepb).'H-NMR( 250 MHz, DMSO-dfc): 5 0.97 (t, 3H), 3.05 (m, 6H), 1.35 (brs. 24H), 1.58(m, 2H), 1.78 (m. 2H). 2.25 (m, IH), 2.35 (t, 2H), 2.51 (m, 3H), 3.97-4 J 8 (m. 5H),4.35 (i, 2H), 6.7 (br s, 2H), 8.1 (br s, IH), 8.5 (br s. 3H). 11.0 (br s. IH).EXAMPLE 13fR)- 2-Ammo-9-Q-stearovloxvmeihvM-fl^-valvloxv')butvOpurineThis example shows the deoxygenation of group R,.a) (R)-2-AT7uno-9-(2-stearoyloxym£thyI-4-(N-ten-butoxycarbonyl-L-vaIyIoxy)butyl)-6-chloropurij)e:To a solution of (R)-9-(2-stearoyIoxymeihyM-{N-iert-buioxycarbonyl-L-valyJoxy)butyl)guaimie from step b of Example 1 (646 mg, 0.9 mmole) inacetonitrile were added tetramethylammonium chloride (427 mg, 2.7 mmole), N.N-dielhylaniline (0.716 ml, 4.5 mmole] and phosphorous oxychloride (0.417 ml.4.5mmole). The reaction was kept under reflux and the progression moniiored byTLC. After 3 hours the reaction mixture w2* evaporated in vacuo and the residuewas dissolved in dichloromethane, then poured into cold sodium hydrogencarbonate aqueous solution, The organic phase was evaporated and purified by silicagel column chromatography. Yield: 251 mg.H'-NMR (CDCLi): & 7 (IH. H-S). 5.43 (fci.2H. NH:), 4 45-4.00 (m. 7H), 2.53(m. IH), 2.28 (t2H). 2.12 (m. IH), 1.75 (m,2H). 1.59 (m.2H), 1.43 (9H), 1.25 (m,b) (R)- 2-Amino-9-(2-stearoyloxmethyl-4-(>J-tert-butoxycarbonyl-L-valyloxy)butyl)purine:To the solution of (R)-2-amino-9-(2-stearoyloxymethyl-4-(N-tert-butoxycarbonyl-L-vaIyIoxy)butyl)-6-chloropurine (240 mg, 0.33 mmole) in methanol / ethyl acetate(6 ml, 3:1 V / V) were added ammonium formate (105 mg, 1.65 mmole) and 10%palladium on carbon (15 mg). The reaction was kept under reflux for 1 hour andrecharged with ammonium formate (70 mg). After one hour more the TLC showedcompletion of the reaction and the mixture was filtered through Celite and washedextensively with ethanol. The filtrate was evaporated and purified by silica gelcolumn. Yield: 193 mg.H'-NMR (CDCL3): 58.69 (s,lH, H-6), 7.74 (s, 1H, H-8), 5.18 (br, s, 2H, NH2), 4.45-4.01 (m, 7H), 2.55 (m, 1H), 2.28 (t, 2H), 2.10 (m, 1H), 1.75 (m, 2H), 1.60 (m, 2H),1.43 (s, 9H), 1.25 (s, 28H), 0.96 (d, 3H), 0.87 (m, 6H).c) (R)-2-Amino-9-(2-stearoyloxymethyl-4-(L-valyloxy)butyl)purine:(R)-2-Amino-9-(2-Stearoyloxmethyl-4-(N-tert-butoxycarbonyl-L-valyloxy)butyl)purine (180 mg, 0.26 mmole) was treated with trifluoroacetic acid(5ml) at 0°C for 40 min. It was then evaporated in vacuo and coevaporatedsuccessively with toluene and methanol. The residue was freeze-dried overnight togive 195 mg of the desired product.'H-NMR (DMSO-rf6): 6 8.78 (s, 1H, H-6), 8.32 (br, 3H), 8.29 (s, IH, H-8), 4.27(t, 2H), 4.13 (d, 2H), 3.98 (t, 2H, 2H), 3.89 (m, 1H), 2.47 (m, 1H), 2.18 (m, 3H),1.43 (m, 2H), 1.23 (28H), 0.93 (m, 6H), 0.85 (t, 3H).EXAMPLE 14Alternative preparation of ffi)-9-[4-Hydroxy-2-(stearoyloxymethyl)butyl]guaniii£a) Preparation of ethyl 4,4-diethoxy-2-ethoxycarbonyl-butyratePotassium tert-butoxide (141.8g, 1.11 equiv.) was dissolved in dry DMF (1 L).Diethyl malonate (266 mL, 1.54 equiv.) was added over 5 minutes.Bromoacetaldehyde diethylacetal (172 mL, 1.14 mole) was added over 5 minutes.The mixture was heated to 120° C (internal temperature), and stirred at 120° C for 5hours. The mixture was allowed to cool to room temperature, poured into water (5L), and extracted with methyl tert-butyl ether (MTBE, 3 x 600 mL). The organicsolution was dried over MgS04, filtered, concentrated, and distilled (0.5 mm, 95-140° C) to yield the desired diester (244 g, 78%) as a colorless oil.'H NMR (CDC13) 5 1.19 (t, 6H), 1.28 (t, 6H), 2.22 (dd, 2H), 3.49 (m, 2H), 3.51 (t,1H), 3.65 (m, 2H) 4.20 (qd, 4H), 4.54 (t, 1H).b) Preparation of 4,4-diethoxy-2-(hydroxymethyl)-butanolLiBH4 (purchased solution, 2M in THF, 22.5 mL) and the product of Example 14step a) (5 g in 15 mL of THF, 18.1 mmol) were combined and warmed to 60° C andstirred at 60° C for 4 hours. The reaction mixture was allowed to cool to roomtemperature and the reaction vessel was placed in a cool water bath. Thentriethanolamine (5.97 mL, I equiv.) was added at such a rate that the temperature ofthe reaction mixture was maintained between 20-25 °C. Brine (17.5 mL) wasadded at a rate such that gas evolution was controlled and the mixture was stirred for45 minutes at room temperature. The layers were separated, the organic layer waswashed with brine (2x15 mL). The combined brine washes were extracted withMTBE (methyl tert-butyl ether, 3 x 20 mL). The combined organic extracts wereevaporated and the residue was dissolved in MTBE (50 mL) and washed with brine(25 mL). The brine layer was back-extracted with MTBE (3 x 25 mL). Thecombined organic extracts were dried over NajSO,, filtered, and concentrated toyield the desired diol (3.36g, 15.5 mmol, 97%) as a colorless oil.lH NMR (CDClj) 8 1.22 (t, 6H), 1.73 (dd, 2H), L92 (m, IH), 2.67 (bs, 2H), 3.52(m, 2H), 3.69 (m, 2H), 3.72 (m, 4H), 4.62 (t, IH).c) Preparation of (2R)-2-acetoxymethyl-4,4-diethoxy-butanolInto a 10 ml 1 neck round bottom flask was charged the product of Example 14 stepb) (3.84 g, 20 mmol), followed by addition of vinyl acetate (2.6 g, 30 mmol) andfinally Lipase PS 30 (69 mg, purchased from (Amano, Lombard, Illinois). Themixture was allowed to stir at ambient temperature for 16 hours. Progress of thereaction was closely monitored by TLC (2 / 1 hexane - EtOAc; stained withCe2(S04)3 and charred on hot plate; r.f. of diol is 0.1, monoacetate is 0.3, bis acetateis 0.75). The reaction mixture was diluted with CH2C12 and filtered through a 5micron filter. The filter was washed with additional CH2C12.The filtrate was then concentrated in vacuo to afford the desired product.d) Preparation of (2S)-2-acetoxymethyl-4,4-diethoxybutyl toluenesulfonateInto a 100 mL 1-neck round bottom flask, equipped with a magnetic stir bar andseptum under N2 was charged the crude product of Example 14 step c) (4.62 g, 19mmol), dry CH2C12 (20 mL) and Et3N (5.62 mL, 40 mmol). To this solution wasadded tosyl chloride (4.76 g, 25 mmol). The resulting mixture was stirred atambient temperature for 4 hours. Charged H20 (0.27 g, 15 mmol) and stirredvigorously for 4 hours. The reaction mixture was diluted with 80 mL EtOAc and 50mL H20 and the aqueous layer was separated. To the organic layer was added 75ml of a 5 % aq. solution of KH2P04. After mixing and separation of the layers, theaqueous layer was removed. The organic layer was washed with 50 mL of saturatedNaHC03 solution, dried over Na2S04, filtered and concentrated in vacuo to aconstant weight of 7.40 g of the desired product.NMR (CDC13) 5 1.17 (t, 6H); 1.62 (m, 2H); 1.94 (s, 3H); 2.19 (m, 1H); 2.45 (s,3H); 3.42 (m, 2H); 3.6 (m, 2H); 4.03 (m, 4H); 4.51 (t, 1H); 7.36 (d, 2H); 7.79 (d,2H).e) Preparation ofInto a 50 mL 1 neck round bottom flask was charged the product of Example 14step d) (3.88 g, 10 mmol), anhydrous DMF (20 mL), 2-amino-4-chloro-purine(2.125 g, 12.5 mmol) and K2C03 (4.83 g). The resulting suspension was stirred at40 °C under a N2 blanket for 20 hours. The mixture was concentrated to removemost of the DMF on a rotary evaporator. The residue was diluted with EtOAc (50mL) and H20 (50 mL). The reaction mixture was transferred to a separatory funnel,shaken and the aqueous layer was separated. The aqueous layer was extracted withEtOAc (25 mL). The organic layers were combined and washed with 5 % KH / P04(75 mL). The organic layer was separated and washed with H20 (75 mL), brine (75mL), dried over Na^C^, filtered and concentrated in vacuo to afford 3.95 g of crudeproduct. The crude product was slurried with 40 mL of methyl-t-butyl ether. Thismixture was stirred overnight at 4°C and the mixture was filtered. The filtrate wasconcentrated to afford 3.35 g of the product as an oil (containing 2.6 g of the desiredproduct based upon HPLC analysis).300 MHz 'H NMR (CDCl3) 5 1.19(m, 6H); 1.69 (2H); 1.79 (s, 1H); 2.03 (s, 3H);2.52 (m, IH); 3.48 (m, 2H); 3.62 (m, 2H); 4.04 (m, 2H); 4.16 (m, 2H); 4.61 (t,lH);5.12 (bs, 2H); 7.81 (s, IH).f) Preparation ofInto a 500 mL 1 neck round bottom flask was charged benzyl alcohol (136 mL),cooled to 0 °C, followed by portionwise addition of KO-t-Bu (36 g, 321 mmol).The temperature was allowed to warm to 40°C, and the mixture was stirred 20minutes. To this mixture was added at 0 °C the crude product of Example 14 step e)(24.7 g, 64.2 mmol) dissolved in 25 mL anhydrous THF and benzyl alcohol (30mL). The temperature was allowed to slowly warm to 8 °C over 2 hours. Thereaction mixture was poured into 500 mL ice and was extracted with 500 mLMTBE. The organic layer was washed with 250 mL of brine, dried over Na^SOj,filtered and concentrated in vacuo to afford 193 g of a benzyl alcohol solution of thedesired product. HPLC analysis indicated that the solution contained 25.96 g of thedesired product.300 MHz lH NMR (CDC13) 5 1.22 (m,6H); 1.55 (2H); 2.18 (m, 1H); 3.15 (m, 1H);3.40 (m, 1H); 3.51 (m, 2H); 3.70 (m, 2H); 4.25 (m, 2H); 4.63 (t,lH); 4.90 (bs, 2H);5.25 (m, 1H); 5.58 (s, 2H); 7.35 (m, 3H); 7.51 (m, 2H); 7.72 (s, 1H).MS = (M + H)+ = 416 (CI).g) Preparation ofInto a 100 mL 1 neck round bottom flask was charged the crude product of Example14 step f) (9.65 g of the benzyl alcohol solution, containing 1.30 g, 3.13 mmol of theproduct of Example 14, step f) dissolved in absolute EtOH (20 mL). To this wasadded 0.45 g of 10 % Pd / C slurried in 5 mL absolute EtOH. The reaction flask wasevacuated and charged with H2 three times with a balloon of H2. The reaction flaskwas pressurized with 1 atm. H2 and the reaction mixture was stirred overnight. Thereaction mixture was filtered through a pad of diatomaceous earth to remove Pd / C.The volatiles were removed in vacuo. The residue was mixed with 25 mL ofisopropyl acetate and then concentrated in vacuo. The residue was diluted withEtOAc (10 mL), seeded with the desired product, heated to reflux and then CH3CN(2 mL) and MTBE (35 ml) were added. The mixture was stirred for 30 minutes.The precipitate was filtered and dried to a constant weight of 600 mg of the desiredproduct.300 MHz lH NMR (d6-DMSO) 5 1.16 (m,6H); 1.45 ( m, 1H); 1.61 ( m, 1H); 2.16(m, 1H); 3.45 (m, 2H); 3.40 (m, 1H); 3.62 (m, 2H); 4.02 (m,2 H); 4.53 (t, 1H); 4.85(t, 1H); 6.55 (bs, 1H); 7.75 (s,lH). MS = (M + H)+ = 416 (CI).h) Preparation ofInto a 25 mL 1 neck round bottom flask was charged the product of Example 14step g) (0.650 g, 2.0 mmol), pyridine (4 mL) and CH2C12 (2 mL), DMAP (lOmg).The mixture was cooled to -5 °C and stearoyl chloride (790 mg, 2.6 mmol)dissolved in CH2C12 (0.5 mL) was added over 5 minutes. The resulting mixture wasstirred 16 hours at -5 °C. Absolute EtOH (0.138 g, 3.0 mmol) was added and themixture was stirred an additional I hour. The reaction mixture was concentrated invacuo. Toluene (30 mL) was added to the residue and then the mixture wasconcentrated in vacuo. Again, toluene (30 mL) was added to the residue and thenthe mixture was concentrated in vacuo. To the residue was added 1 % KH2P04 (25mL) and this mixture was extracted with CH2C12 (60 mL). The organic layer wasseparated and was dried over NajSC^, filtered and concentrated in vacuo to aconstant weight of 1.65 g. The crude product was chromatographed on 40 g ofSi02, eluting with 95 / 5 CH2C12- EtOH, affording 367 mg of the desired product.300 MHz !H NMR (CDC13) 6 0.89 (t, 3H); 1.26 (m, 30 H); 1.65 (m,3 H); 2.32 (m,IH); 3.45 (m, 1 H); 3.60 (m, 2H); 4.08 (m, 2H); 4.60 (m, 1 H); 6.0 (bs, 2H); 7.53(s, I H).i) Preparation ofInto a 25 mL 1 neck round bottom flask was charged the product of Example 14,step h) (0.234 g, 0.394 mmol) dissolved in THF (1.7 mL). To this solution wasadded triflic acid (0.108 g) in H20 180 mg. The mixture was stirred overnight atroom temperature. To the reaction mixture was added saturated NaHC03 solution(10 mL), THF (5mL), CH2C1; (2 mL) and NaBH, (0.10 g). This mixture wasstirred for 30 minutes. To the reaction mixture was added a 5 % solution of KH2P04(30 mL). This mixture was extracted with 2 x 15 ml of CH2C12. The organic layerswere combined and dried over Na^O^ filtered and concentrated in vacuo to aconstant weight of 207 mg. This material was recrystallized from EtOAc (8 mL)and CHjCN (0.5 mL) affording 173 mg of the desired product.300 MHz 'H NMR (d6-DMSO) 5 0.82 (t, 3H); 1.19(m,30H); 1.41 (m,4H);2.l9(t, 2H); 2.32 (m, IH); 3.40 (m, 2H); 3.9 (m, 4H); 4.49 (m, IH); 6.4 (bs, 2H); 7.61(m, 1.5H); 9.55 (m, 0.5H).EXAMPLE 15■iAlternative preparation of (R)-9-[4-fN-tert-butyloxycarboryl-L-valyloxyV2-(stearovloxymethyn butyl] guanine(R)-9-[2-(StearoyloxymethyI)-4-(t-butyldiphenylsilyloxy)butyl]guanine (45g) andTHF (950 ml) were combined in a 2L flask. Then Boc-L-valine (3.22 g, 0.25 eq)was added, followed by tetrabutylammonium fluoride (1M in THF, 89,05 mL) over10 minutes. The clear reaction mixture was stirred at room temperature for 2 hoursand 50 minutes with monitoring of the reaction progress by TLC (90 / 10iCH2Cl2 / MeOH).To the reaction mixture was added Boc-L-valine (35.43 g, 2.75 eq), DCC (36.67 g,2.75 eq) and dimethylaminopyridine (1.1 g, 0.15 eq) in THF (25 ml). The reactionmixture was stirred at room temperature for 24 hours. DCU was filtered off andwashed with CH2Cl2. The filtrate was concentrated, and the residue was taken up in2 litres of CH2CL2and washed with 2L of / 2 saturated sodium bicarbonate and brinesolutions. On drying and evaporation, approximately 100 g of crude product wasobtained. The material was purified by silica chromatography (6000 ml of silica)using 3% MeOH / CH2a2 to 5% MeOH / CH2Cl2 to obtain 38.22 mg of the desiredproduct.EXAMPLE 16Alternative preparation of (RV9-[2-(stearoyloxymethyl)-4-(L-valyloxy)butvljguaninea) (R)-9-[2-Hydroxymethyl)-4-(t-butyldiphenylsilyloxymethyl)butyl]guanineH2G (450.0 g, 1.78 mol) and N,N dimethylformamide (6.4 kg) were charged into aBucchi evaporator and the mixture warmed to dissolve the solid. The solution wasconcentrated to dryness tinder vauum at no more than 90°C. The resulting powderwas transferred to a 22 litre flask with stirrer, addition funnel and and temperatureprobe. N,N-dimethylformamide (1.7 kg) was added followed by pyridine (3.53 kg).The resulting suspension was cooled to -10°C under nitrogen and stirred at -5 ±5°Cas t-butylchlorodiphenylsilane (684 g, 2.49 mol) was added dropwise. The resultingmixture was stirred at -5 ±5°C until the reaction was complete (as monitored byTLC (10:1 methylene chloride / methanol) and HPLC (4.6 x 250 mm Zorbax RxC8(5 micron); 60:40 acetonitrile-aq. NH4OAC (0.05 M) at 1.5 ml / min; UV detectionat 254 nm)). Water (16 kg) was added and the mixture was stirred for 30 minutes toprecipitate the product, then the mixture was cooled to 0°C for 30 minutes. Thesolid was isolated by filtration and the product cake was washed with cold water andsucked dry with air to provide the crude product as an off-white solid. The crudesolid was taken up in pydridine (3 kg) and concentrated under vacuum at 60°C toremove water. The dry solid residue was slurried with methanol (10 kg) at 60°C for1-2 hours and filtered while hot. The filtrate was concentrated under vacuum and thesolid residue was refluxed with isopropyl acetate (7 kg) for 30 minutes. The mixturewas cooled to 20°C and filtered. The filter cake was dried under vacuum at 50°C toprovide the title compound as a white solid (555 g).b) (R)-9-[2-(Stearoyloxymethyl)-4-(t-butyldiphenylsilyloxy)butyl]guanineThe product of Example 16, step a) (555 g, 1.113 mol) was charged to a 50 litre°uchi evaporator Pyridine (2 7 kg) was added dropwise to dissolve the solid andthe mixture was distilled to dryness under vacuum at 60°C. The residue was takenup in fresh pyridine (2.7 kg) and transferred to a 22 litre flask with stirrer, additionfunnel and temperature probe. The solution was cooled to -5°C under nitrogen. Asolution of stearoyl chloride (440 g, 1.45 mol) in methylene chloride (1.5 kg) wasadded so as to maintain a temperature below 0°C. 4-(N,N-dimethylamino)pyridine(15 g, 0. 12 mol) was added and the mixture was stirred at -5 - 0°C for 2-4 hoursuntil conversion was complete (as monitored by TLC (10:1 methylenechloride / methanol) and HPLC (4.6 x 250 mm Zorbax RxC8 (5 micron); 60:40acetonitrile-aq. NH4OAc (0.05 M) at 1.5 ml / min; UV detection at 254 nm)). At theend of the reaction, acetonitrile (8.7 kg) was added and the mixture was stirred fornot less than 15 minutes to precipitate the product. The slurry was cooled to 0°C for2 hours and the solid isolated by filtration and the filter cake washed withacetonitrile (2 kg). The desired product was obtained as a white solid (775 g).c) (R)-9-[4-Hydroxy-2-(stearoyloxymethyl)butyl]guanineA solution of the product of Example 16, step b) (765 g, 0.29 mol) intetrahydrofuran (10 kg) was prepared in a reactor. A solution oftetra(n-butyl)ammonium fluoride in tetrahydrofuran (1.7 kg of 1 M solution, 1.7mol) was added and the resulting clear solution was stirred at 20 ± 5°C for 4 hours.Water (32 kg) was added and the resulting slurry was stirred for 1 hour and thencooled to 0°C for 30 minutes. The precipitate was isolated by filtration and the filtercake was washed successively with water (10 kg) and acetonitrile (5 kg). Afterdrying under vacuum at 25°C, 702 g of crude product was obtained. The crudeproduct was dissolved in refluxing THF (4.2 kg) and water (160 g), then cooled to40°C and treated with methylene chloride (14.5 kg). The mixture was allowed tocool to 25±5°C for I hour, then it was cooled to 5±5°C for 1 hour to completeprecipitation. The slightly off-white powder was isolated by filtration and driedunder vacuum at 40°C to yield the desired product (416 g).d) (R)-9-[4-(N-Cbz-L-valyloxy)-2-(stearoyloxymethyl)butyl]guanineA solution of N-Cbz-L-valine (169 g, 0.67 mol) in diy THF (750 ml) was preparedin a 2 litre flask with mechanical stirrer, thermometer and addition funnel Asolution of dicyclohexylcarbod«imide (69.3 g, 0.34 mol) in THF (250 ml) was addedover 5 minutes and the resulting slurry was stirred at 20±5°C for 2 hours. The slurrywas filtered and the filter cake was washed with THF (300 ml). The filtrate andwash were charged to a 3 litre flask with stirrer and thermometer. The product ofExample 16, step c) (116 g, 0.22 mol) was added as a solid, with a rinse of THF(250 ml). 4-(N,N-dimethylamino)pyridine (2.73 g, 0.022 mol) was added and thewhite slurry stirred at 20±5°C. Within 15 minutes, the solids were all dissolved andthe reaction was complete within 1 hour (as determined by HPLC: 4.6 x 250 mmZorbax RxC8 column; 85:15 acetonitrile- 0.2 % aq. HC104at 1 ml / min.; UVdetection at 254 nm; starting material elutes at 4.1 min. and product elutes at 5.9min.). The reaction was quenched by addition of water (5 ml) and the solution wasconcentrated under vacuum to leave a light yellow semisolid. This was taken up inmethanol (1.5 litres) and warmed to reflux for 30 minutes. The solution was cooledto 25°C and the precipitate was removed by filtration. The filtrate was concentratedunder vacuum to leave a viscous, pale yellow oil. Acetonitrile, (1 L) was added andthe resulting white suspension was stirred at 20 ±5°C for 90 minutes. The crudesolid product was isolated by filtration, washed with acetonitrile (2 x 100 ml) andair-dried overnight to provide the desired product as a waxy, sticky solid (122 g).This was further purified by crystallization from ethyl acetate (500 ml) and dryingunder vacuum at 30°C to provide the desired product as a white, waxy solid (104 g).e) ( / ?)-9-[4~(L-valyIoxy)-2-(stearoyIoxymethyl)butyl]guanineA solution of the product of Example 16, step d), (77 g) in warm (40°C) ethanol(2 3 L) was charged to an hydrogenation reactor with 5 % Pd-C (15.4 g). Themixture was agitated at 40°C under 40 psi hydrogen for 4 hours, evacuated andhydrogenated for an additional 4-10 hours. The catalyst was removed by filtrationand the filtrate was concentrated under vacuum to provide a white solid. This wasstirred with ethanol (385 ml) at 25°C for 1 hour, then cooled to 0°C and filtered.The filter cake was dried with air, then under vacuum at 35°C to yield the titlecompound as a white powder (46 g).EXAMPLE 17fRV942-fL-Valvloxymethyn-4-f.Mearovloxvlbutvnguaninea) (R)-9-[2-Hydr0xymethyJ-4-(stear0Yl0xy)butyI]guanine.H2G (506 mg; 2.0 mmol) was dissolved in dry N,N-dimeihy]formamide (40 ml)with pyridine (400 mg; 5.06 mmol) and 4-dimethylaminopyridine (60 mg; 0.49mmol). Stearoyl chloride (]500 mg; 4.95 mmoj) was added and the mixture keptovernight at room temperaiure. Most of the solvent was evaporated in vacuo, theresidue stirred with 70 mi ethyl acetate and 70 mJ water, and the solid filtered off,washed with ethyl acetate and water and dried to yield 680 mg of crude product.Column chromatography on silica gel (chioroformrmethanol 15:1) gave pure titlecompound as a white solid.NMR (DMSO-cfg) 5: 0.86 (I, 3H); 1.25(sf28H); 1.51 (qui,2H); 1.62(m,2H);2.06 (m, IH); 2.23 (t, 2H); 3.34 (d, 2H); 3.96 (ABX, 2H); 4.07 (dd, 2H); 6.30 (br s,"2H); 7.62 (s, IH); 10.45 (s, IH).I3c NMR (DMSO-^6) 6: 13.8 (C18); 22.0 (C17); 24.4 (C3); 27.7 (C3'); 28.4-28.S(C4-6, C15); 28.9 (C7-14); 11.2 (C16); 33.5 (C2); 38.0 (C2'); 44.0 (CI'); 60.6 / 61.8(C4', C2"); 116.5 (guaC5); 137.7 (guaC7); 151.4 (guaC4); 153.5 (guaC2); 156.7(guaC6); 172.7 (COO).b) (R)-9-[2-(N-Boc-L-valyloxymetby))-4-(stcaroyloxy)butyl]guanine.A mixture of N-Boc-L-va!ine (528 mg; 2.1 mmol) and N.N-dicyclohexylcarbodiimide (250 mg; 3.21 mmol) in dichloromethane (20 ml) was stirred overnightat room temperature, dicyclohexylurea filtered off and extracted with a smallvolume of dichloromethane, and the filtrate evaporated i?i vacuo to a small volume.(fi)-9-[2-Hydroxymethyl-4-(stearoy}oxy)butyJ]guanine (340 mc; 0.654 mmol). A-dimeihylaminopyridine (25 mg; 0.205 mmol), and dry N'.N'dimethylformamide (15ml) were added end the mixture was stirred for 4h at 50°C under Nn. The solventwas evaporated in \>ccuo to a .small volume. Column chromatography on silica gel,then on aluminum oxide (ethyl acetate:methanol: water 15:2:1 a5 eluent) gave 185mg (39%) pure title compound as a white solid.'H NMR (C / / CI3) 6: 0.85-1.0 (m, 9H) I8-CT3, CH(CH3)2\ 1-25 (s, 28H) 4-17-CH2; 1.44 (s, 9H) t-Bu; 1.60 (qui, 2H) 3-CH2; 1.74 (qua, 2H) 3'-CH2; 2.14 (m, 1H)2'-CH; 2.29 (t, 2H) 2-CH2; 2.41 (m,lH) Ctf(CH3)2; 4.1-4.3 (m, 6H) Clr-CH2, C2"-CH2, C4-CH2; 5.4 (d, 1H) ctCH; 6.6 (br s, 2H) guaNH2; 7.73 (s, 1H) guaH8; 12.4(brs).13c NMR (C / / CI3) 5: 13,9 (CIS); 17,5 / 18.9 (2 Val CH3); 22.4 (C17); 24.7 (C3);28.1 (C3'); 28.9-29.3 (C4-6, CIS); 29.4 (C7-14); 30.7 (Val pC); 31.7 (C16); 34.0(C2); 35.9 (C2'); 43.9 (CI1); 58.7 (Val ccC); 61.4 / 63.6 (C4\ C2"); 79.9 (CMe3);116.4 (guaC5); 137.9 (guaC7); 151.7 (guaC4); 153.7 (guaC2); 155.7 (CONH);158.8 (guaC6); 172.1 (CHCOO); 173.5 (CH2COO).c) (R)-9-[2-(L-Valyloxymethyl)-4-(stearoyloxy)butyl]guanine.Chilled trifluoroacetic acid (2.0 g) was added to (£)-9-[2-(N-Boc-L-valyloxymelhyl)-4-(stearoyloxy)butyl]guanine (180 mg; 0.25 mmol) and thesolution kept at room temperature for Ih, evaporated to a small volume, andlyophilized repeatedly with dioxane until a white amorphous powder was obtained.The yield of title compound, obtained as the trifluoracetate salt, was quantitative.'H NMR (DMSO-d6) 5: 0.87 (t, 3H) 18-CHh 0.98 (dd, 6H) CH(CH3)2; 1.25(Sj 28H) 4-17-CH2; 1.50 (qui, 2H) 3-CH2; 1.68 (qua, 2H) 3'-CH2; 2.19 (m, 1H) 2'-CH; 2.26 (t, 2H) 2-CH2; 2.40 (m,lH) C / / (CH3)2; 3.9-4.25 (m, 7H) C1'-CH2, C2"-CH2) C4-CH2, aCH; 6.5 (br s, 2H) guaNH2; 7.79 (s, 1H) guaH8; 8.37 (br s, 3H)NH3+; 10.73 (brs, IH) guaNH.13C NMR (DMSO-d6) 8: 14.2 (C18); 17.9 / 18.3 (2 Val CH3); 22.3 (C17); 24.6 (C3);27.7 (C3'); 28.7-29.1 (C4-6, C15); 29.2 (C7-14); 29.5 (Val pC); 31.5 (C16); 33.7(C2); 35,0 (C2'); 44.1 (CV); 57.6 (Val aC); 61.6 / 65.2 (C4\ C2"); 116.1(guaC5);l 16.3 (qua, J290Hz, CF3); 137.9 (guaC7); 151.5 (guaC4); 154.0 (guaC2);156.7 (guaC6);158.3 (qua, / 15Hz. CF3COO) 169.1 (CHCOO); 173.1 (CH2COO).EXAMPLE 18Alternative preparation of (R)-9-[2-hydroxymethyl-4-(stearoyloxy)butyl]guanineH2G (7.60 g, 30 mmol) was heated to solution in dry DMF (200 ml). The solutionwas filtered to remove solid impurities, cooled to 20° C (H2G cystallized) andstirred at that temperature during addition of pyridine (9.0 g, 114 mmol), 4-dimethylaminopyridine (0.46 g, 3.75 mmol) and then, slowly, stearoyl chloride(20.0 g, 66 mmol). Stirring was continued at room temperature overnight. Most ofthe solvent was then evaporated off in vacuo, the residue stirred with 200 ml ethylacetate and 200 ml water and the solid filtered off, washed with ethyl acetate andwater and dried to yield crude product. As an alternative to recrystallization, thecrude product was briefly heated to almost boiling with 100 ml of ethyl acetate:methanol: water (15:2:1) and the suspension slowly cooled to 30° C and filtered toleave most of the 2" isomer in solution (the 2" isomer would crystallize at lowertemperature). The extraction procedure was repeated once more to yield, afterdrying in vacuo, 6.57 g (42%) of almost isomer free product.EXAMPLE 19Preparation of crystalline fll)-9-[2-stearoyloxymethyl)-4-(L-valyloxy)butyl]guanineThe product of Example 16, step c) (20.07 g, 32.5 mmol) was dissolved in absoluteethanol (400 ml) with heating, filtered, and further diluted with ethanol (117.5 ml).To this solution was added water (HPLC grade, 103.5 ml), and the mixture wasallowed to cool to 35-40°C. After the mixture was cooled, water (HPLC grade,931.5 ml) was added at a constant rate over 16 hours with efficient stirring. After allthe water was added, stirring was continued for 4 hours at room temperature. Theresulting precipitate was filtered through paper and dried under vacuum at roomtemperature to obtain the title compound as a white, free flowing crystalline powder(19.43 g, 97%), m pt 169-170 °C.EXAMPLE 209-R-(4-Hydroxy-2-(L-valyloxymethyl)butyl) guaninea) To a solution of 9-R-(4-(tert-butyldiphenyIsiIyIoxy)-2-(hydroxymethy!)butyl)guanine (695 mg, 1.5 mmole) in DMF (30 ml) wereadded N-Boc-L-Valine (488 mg, 2.25 mmole), 4-dimethylamino pyridine(30 mg, 0.25 mmole) and DCC (556 mg, 2.7 mmole). After 16 hr, thereaction was recharged with N-Boc-L-valine (244 mg) and DCC (278 mg),and was kept for an additional 5 hours. The reaction mixture was filteredthrough Celite and poured into sodium hydrogen carbonate aqueous solution,and then it was extracted with dichloromethane. The organic phase was■ievaporated and purified by silica gel column chromatography, giving 950mg the N-protected monoamino acyl intermediate.b) The above intermediate (520 mg, 0.78 mmole) was dissolved in THF(15 ml). To the solution was added hydrogen fluoride in pyridine (70 % / 30 %, 0.34 ml). After two days, the solution was evaporated andcoevaporated with toluene. Purification by silica gel column chromatographygave 311 mg of the protected monoamino acyl compound.'H-NMR (DMSO-d6): 5 10.41(s, IH), 7.59 (IH), 6.26 (br s, 2H), 4.32 (t,IH), 3.95 (m, 5H)S 3.46 (m, 2H), 2.41 (m, IH), 2.06 (m, IH), 1.45 (m, 2H),1.39 (s, 9H), 0.90 (d, 6H).c) The product of step b) (95 mg, 0.21 mmole) was treated with amixture of trifluoroacetic acid (4 ml) and dichloromethane (6 ml) for 1 hr.The solution was evaporated and freeze-dried, give 125 mg of theunprotected monoaminoacyl product.'H-NMR (DjO): 6 8.88 (s, 1H), 4.32 (m, 4H), 3.96 (d, 1H), 3.68 (m, 2H),2.63 (m, 1H), 2.22 (m, 1H), 1,73 (m, 2H), 1.00 (m, 6H).EXAMPLE 21(RV9-(2-Hydroxymethvl-4-(L-isoleucyloxy)butyl) guaninea) To a solution of (R)-9-(2-hydroxymethyl-4-hydroxybutyl)guanine(2.53 g, 10 mmole) in DMF (250 ml) were added N-Boc-L-isoleucine(2.77 g,12 mmole), 4-dimethylaminopyridine (61 mg, 0.6 mmole) and DCC (3.7 g,18 mmole). After reaction for 16 hrat 0°C, N-Boc-L-isoleucine (1.3 g) andDCC (1.8 g) were recharged, and the reaction was kept overnight at roomtemperature. The reaction mixture was filtered through Celite and the filtratewas evaporated and purified by silica gel column chromatography, giving1.25 g of the N-protected monoamino acyl inteimediate.lH-NMR (DMSO-d6): 5 10.56 (s, 1H), 7.62 (s, IH), 6.43 (s, 2H), 4.75(t, IH), 4.15 - 3.80 (m, 5 H), 3.25 (m, 2H) 2.05 (m, 1H), 1.80-1-05 (m, 14H),0.88 (m, 6H).b) The intermediate from step a) (100 mg, 0.21 mmole) was treated withtrifluoroacetic acid (3 m) and for 30 min at 0°C. The solution was evaporatedand freeaze-dried, give the titled unprotected mono-aminoacyl product inquantitative yield.'H-NMR (DMSO-d6 + D20): 5 8.72 (s, IH), 4.15 (m, 4H), 3.90 (d, IH), 3.42(m, 2H), 2.09 (m, IH), 1.83 (m, IH), L61 (m, 2H), 1.15 (m, H), 0.77 (d, 3H), 0.71(t, 3H).EXAMPLE 22(R)-9-[2-Hydroxymethyl-4-(J L-valylaxv)butvJ]guanineThe product of Example 1, step a) was deprotected with trifluoroaacetic acid in thesame manner as Example 1, step c)'H-NMR (250 MHz, DMSO-d6): 5 1.04 (dd, 6H), 1.55-1.88 (m, 2H), 2.21 (m, 2H),3.48 (m, 2H), 4.00 (m, IH), 4.13 (m, 2H), 4.34 (t, 2H), 6.9 (br s, 2H), 8.21 (s, IH),8.5 (br s, 3H), 11.1 (brs, IH).EXAMPLE 23(RV9-[ 2-< L-Valyloxvmethyl>-^-(valvloxv)butvl] guaninea) (R)-9~[4-(N-Boc-l-valyloxy)-2-(N-Boc-l-vaIyIoxymethyl)butyl]guanineApplication of the technique described in Example 1, step a), but using 2.7 eqs, 0.28eqs,-and 3.2 eqs of N-Boc-l-valine, DMAP, and DCC, respectively, resulted in thetitle compound,lHNMR (250 MHz, CHCI3) 5: 0.95 (m, 12H), 1.42 (brs, 18H), 1.8 (m, 2H), 2.14(m, 2H), 2.47 (m, IH), 4.0-4.4 (m, 8H), 6.5 (br s, 2H), 7.67 (s, IH).b) (R)-9-[4-(i.-VaIyloxy)-2-(L-valyIoxymethyl)butyl]guanineThe titled compound was obtained as the tris-trifluoroacetate salt from theintermediate of Example 20 step a) by deprotection in a manner analogous toExample 1 step c).IH NMR (250 MHz, DzO) 6: 1.0 (m, 12H), 1.89 (m, 2H), 2.29 (m, 2H), 2.62 (m,IH), 4.02 (dd, 2H), 4.38 (m, 6H), 4.89 (br s, ca. I0H), 8.98 (s, IH).EXAMPLE 24rRVQ-^-hvdroxy^-fstearovloxymethyllbutvljguanineThe titled compound is prepared according to steps a) to c) of Example 7.JH NMR (250 MHz, DMSO-^ ): 6 10.52 (s, IH), 7.62 (s, 1H), 6.39 (s, 2H), 4.50 (t,IH), 3.93 (m,4H), 3.42 (m, 2H), 2.45 (m, IH), 2.23 (t, 2H), 1.48(m,4H), 1.22 (s,2SH), 0 89 (t, 3H)EXAMPLE 25rRV9-[2-Hydroxymcthyl-4-(stearQ>jQxy)butyl]guaiiine.The titled compound is prepared by the procedure of Example 17, step a)^H NMR (DMSO-< / 6) 0-86 (t, 3H); 1.25 (s, 28H); 1.51 (qui, 2H); 1.62 (m, 2H);2.06 (m, IH); 2.23 (t, 2H); 3.34 (d, 2H); 3.96 {ABX, 2H); 4.07 (dd, 2H); 6.30(br s, 2H); 7.62 (s, IH); 10.45 (s, IH).EXAMPLE 26Alternative preparation of (R)-9-[2-stearoyloxymethvl)-4^L-valyloxy)butvl]guaninea) ^ (R)-9-[4-N-benzyloxycarbonyl-L-valyloxy)-2-(hydroxymethyl)-butyl]guanineDry H2G (252 mg, lmmol), 4-dimethylaminopyridine (122 mg, 1 mmol) and N-Cbz-L-valine p-nitrophenyl ester (408 mg, 1.1 mmol) were dissolved in drydimethyl formamide (16 ml). After stirring at 23°C for 30 hours, the organic solventwas removed and the residue carefully chromatographed (silica, 2%-7%methanol / methylene chloride) to afford the desired product as a white solid (151mg, 31%).b) (R)-9-[4-N-benzyIoxycarbonyl-L-valyloxy)-2-(stearoyloxymethyl)-butyl]guanineA solution of stearoyl chloride (394 mg, 1.3 mmol) in dry methylene chloride (2 ml)was added slowly dropwise under nitrogen to a solution of the product of step a)(243 mg, 1 mmol) and 4-dimethylaminopyridine (20 mg) in dry pyridine (5 ml) at-5°C. The reaction mixture was stirred at that temperature for 12 hours. Methanol (5ml) was added and the reaction stirred for 1 hour. After removal of the solvent, theresidue was triturated with acetonitrile and chromatographed (silica, 0-5%methanol / methylene chloride) to afford the desired product (542 mg, 72%).c) (R)-9-[2-steBXoyloxymeihyI)-4~<L-valyloxy)buty]] guanine"Hie product of step b) (490 mg, 1 mmol) was dissolved in methanol (30 ml) and 5%Pd / C (100 mg) added. A balloon filled with hydrogen was placed on top of thereaction vessel, After 6 hours at 23°C, TLC showed the abscnce of starting material.The reaction mixture was filtered through a 0.45 micron nylon membrane to removethe catalyst and the solvent wa6 removed to afford the desired product as a whitesolid (350 mg, 99%) which was identical (spectral and analytical data) to Example16.EXAMPLE 27Alternative preparation of fRV9 - / 4~hyflrory-2-rt.-va1y1flxymethvn- butyl)yuanine(R)-9-(4-(L-valyIoxy)-2-(L-valyloxymethyI) butyl)guanine from Example 23 step b)(100 mg, 0,126 mmole) was dissolved in 0.1 N NaOH aqueous solution (6.3 ml,0.63 mmole) at room temperature. At intervals, an aliquot was taken andneutralized with 0.5 N trifluoroacetic acid. The aliquots were evaporated andanalyzed by HPLC to monitor the progress of the reaction. After 4 hours, 0.5 Ntrifluoroacetic acid solution (1.26 ml, 0.63 mmole) was added to the solution andthe reaction mixture was evaporated. The desired product was purified by HPLC,(YMCf 50 x 4.6 mm, gradient 0.1% TFA + 0-50% O.lVo TFA in acetonitrile, in 20minutes, UV detection at 254 nm. Yield: 13.6 %'H-NMR(DaO)-. 5 8.81 (s, IH), 4.36 (m, 4H), 4.01 (d, 1H), 3.74 (m, 2H)« 2.64 (m,IH), 2.25 (m, IH), 1.73 {m, 2H), 1.03 (dd, 6H).EXAMPLE 28Altemarivg preparation nf (R).Q,(2-hydmyymethyI>4-ri^valyJoxy)butyl)glianineHPLC separation of the reaction solution from Example 27 gave the titledcompound in 29.2% yield.'H-NMR (DMSO^): 5 8.38 (s, 3H), 8.26 (s, IH.), 6.83 ( br s, 2H), 4.23 (m, 2H),4.06 (ra, 2H), 3.91 (m, 1 H>, 3.40 (m, 2H), 2.19 (m, 2H), 1.8 -1.40 (m, 2H), 0.95 (dd,6H).EXAMPLE 29rRV9>f2-ste^ov1nxymetliyl)-4-rr^v^ylQxy>]bmylguanTne m on oh ydro chlorideThe product of Example 16, step d) (360 mg, 0.479 mmol) was dissolved in amixture of methanol (10 ro)) and ethyl acetate (10 ml). To the solution was added10% Pd / C (100 mg) and IN HC1 (520 microlitres). The reaction mixture was stirredat room temperature for 2 hours under 1 atm. H2. The reaction mixture was filteredand the solvent evaporated from the filtrate to provide the desired product as acrystalline solid (300 mg).FORMULATION EXAMPLE ATablet formulationThe following ingredients are screened through a 0.15 mm sieve and dry-mixed10 g (R)-9-[2-(8tearoyloxymethyl)-4-(L-vaIyIoxy)butyl]guanijie40 g lactose49 g crystalline cellulose1 g magnesium stearatcA tabletting machine is used to compress the mixture to tablets containing 250 mgof active ingredient.FORMULATION EXAMPLE BEnteric cftaterf *ahli»tThe tablets of Formulation Example A are spray coated in a tablet coater with asolution comprising120 g ethyl cellulose30 g propylene glycollOg sorbitan monooleatead 1 000 ml aq. dist.FORMULATION EXAMPLE CControlled release formulation50 g (R)-9-[2-(stearoyloxymethyl)-4-(L-vaIyIoxy)butyl]guanine12 g hydroxypropylmethylcellulose (Methocell K15)4.5 g lactoseare dry-mixed and granulated with an aqueous paste of povidone. Magnesiumstearate (0.5 g) is added and the mixture compressed in a tablctting machine to 13mm diameter tablets containing 500 mg active agentFORMULATION EXAMPLE DSPftXBpsulefl250 g (R)-9-[2-(stearoyIoxymethyl>4-{L-valyloxy)butyl]guanine100 g lecithin100 jg aracbis oilThe compound of the invention is dispersed in the lecithin and aracbis oil and filledinto soft gelatin capsules.BIOLOGY EXAMPLE IBioavailability testing- in rat«The bioavailability of compounds of the invention were compared to the parentcompound H2G and other H2G derivatives in a rat model. Compounds of theinvention and comparative compounds were administered, per oral (by catheter intothe stomach), to multiples of tlirec individually weighed animals to give 0.1mmol / kg of the dissolved prodrug in an aqueous (Example 4, 5, Comparativeexample 1 - 3, 5), peanut oil (Comparative examples 4,9,10) or propylene glycol(Example 1 - 3, 6 -12, Comparative example 6, 7) vehicle dependent cm thesolubility of the test compound ingredient. The animals were fasted from 5 hoursbefore to approximately 17 hours after administration and were maintained inmetabolic cages. Urine was collected for the 24 hours following administration andfrozen until analysis. H2G was analysed in the urine using the HPLC / UV assay ofStShle & Oberg, Antiroicrob Agents, Chemother. 36 No 2, 339-342 (1992), modifiedas follows: samples upon thawing are diluted 1:100 in aq dist HjO and filteredthrough an amicon filter with centrifugation at 3000 rpm for 10 minutes. Duplicate30 til samples are chromatographed on an HPLC column; Zortax SB-C18; 75 x 4.6mm; 3.5 micron; Mobile phase 0.05M NH«P04,3 - 4 % methanol, pH 3.3 - 3.5; 0.5ml / min; 254 nm, retention time for H2G at MeOH 4%andpH 3 .33, -12.5 min.Bioavailability is calculated as the measured H2G recovery from each animalaveraged over at least three animals and expressed as a percentage of the averaged24 hour urinary H2G recovery from a group of 4 individually weighed ratsrespectively injected i.v.jugularis with 0.1 mmol / kg H2G in a Ringer's buffervehicle and analysed as above.Comparative example J (H2G) was from the same batch as used for preparation ofExamples I to 12. The preparation of Comparative example 2 (mono Val-H2G) and3 (diVaJ-H2G) are shown in Examples 20 and 23. Comparative example 4(riistearoyl H2G) was prepared by di-esterification of unprotected H2G incomparable esterification conditions to step b of Example 1. Comparativeexamples 5 & S (Vai / Ac H2G) were prepared analogously to Example 4 using aceticanhydride with relevant monovaline H2G. Comparative example 6 (Ala / stearoylH2G) was prepared analogously to Example 6 using N-7-Boc-L-alanine in step 4.Comparative example 7 (Glv / decanoyl) was prepared analogously to Example 5 butusing the step a intermediate made with N- / -Boc-L-g!ycine. The preparation ofComparative examples 9 and 10 in shown in Examples 24 and 25 respectively. Theresults appear on Table 2 overleaf:Comparison of the bioavailabilities of the compounds of the invention with thecomparative examples indicates that the particular combination of the fatty acids atR, / Rj with the amino acids at produces bioavailabilities significantly greaterthan the corresponding diamino acid ester or di fatty acid ester. For example, in thismodel, the compound of Example 1 displays 55 % better bioavailability than thecorresponding divaline ester of Comparative example 3. The compound of Example4 displays 25 % better availability than the corresponding divaline ester.It is also apparent, for instance from Comparative examples 5, 6 and 7 that only thespecified fatty acids of this invention in combination with the specified amino acidsproduce these dramatic and unexpected increases in pharmacokinetic parameters.BIOLOGY EXAMPLE 2Plasma concentrations in ratsA plasma concentration assay was done in male Sprague Dawley derived rats. Tireanimals were fasted overnight prior to dosing but were permitted free access towater. Each of the compounds evaluated was prepared as a solution / suspension inpropylene glycol at a concentration corresponding to 10 mg H2G / ml and shaken atroom temperature for eight hours. Groups of rats (at least 4 rats in each group)received a 20 mg / kg (2 ml / kg) oral dose of each of the compounds; the dose wasadministered by gavage. At selecteditime points after dosing (0.25, 0.5, 1,1.5,2,4,6, 9,12, 15, and 24 hours after dosing), heparinized blood samples (0.4 ml / sample)were obtained from a tail vein of each animal. The blood samples were immediatelychilled in an ice bath. Within two hours of collection, the plasma was separatedfrom the red cells by centrifugation and frozen till analysis. The components ofinterest were separated from the plasma proteins using acetonitrile precipitation.Following lyophilisation, and reconstitution, the plasma concentrations weredetermined by reverse phase HPLC With fluorescence detection. The oral uptake ofH2G and other test compounds was dietermined by compari son of the H2G areaunder the curve derived from the oral dose compared to that obtained from a J Omg / kg intravenous dose of H2G, administered to a separate group of rats. Theresults are depicted in Table IB above.BIOLOGY EXAMPLE 3Bioavailability in monkg / gThe compounds of Example 1 and Comparative example 3 (see Biology Example 1above) were administered p.o. by gavage Co cynomolgus monkeys. The solutionscomprised:Example J 150 mg dissolved in 6.0 ml propylene glycol, correspondingto 25 mg / kg or 0.0295 mmoMcg.Comparative 164 mg dissolved in 7.0 ml water, corresponding to 23.4Example 3 mg / kg or 0.0295 mmol / kg.Blood samples were taken at 30 min, 1,2, 3,4,6,10 and 24 hours. Plasma wasseparated by centrifugation at 2500 rpm and the samples were inactivated at 54°Cfor 20 minute6 before being frozen pending analysis. Plasma H2G levels weremonitored by the HPLC / UV assay of Example 30 above.Figure 1 depicts the plasma H2G recovery as a function of time. Although it is notpossible to draw statistically significant conclusions from single animal trials, it: appears that the animal receiving the compound of the invention experienced asomewhat more rapid and somewhat greater exposure to H2G than the animal which; received an alternative prodrug of H2G."BIOLOGY EXAMPLE 4! Antiviral activityHerpes simplex virus-1 (HSV-l)- infected mouse serves as an animal model todetermine the efficacy of antiviral agents in vivo. Mice inoculated mtraperitoncallywith HSV-1 at 1000 times the LDS0 were administered cither with a formulationcomprising the currently marketed anti-herpes agent acyclovir (21 and 83 mg / kg ina 2% propylene g}yco7 in sterile water vehicle, three times daily, p.o.) or thecompound of Example 16 (21 and S3 mg / kg in a 2% propylene glycol in sterilewater vehicle, three times daily, p.o.) for 5 consecutive days beginning 5 hours afier'inoculation. The animals were assessed daily for deaths. The results are displayed inFigure 2 which charts the survival rate against time. In the legend, the compound ofthe invention is denoted Ex.29 and acyclovir is denoted ACV. The percentage ofmice surviving tbeHSV-l infection was significantly greater following a given doseof the compound of the invention relative to an equivalent dose of acyclovir.The foregoing is merely illustrative of the invention and is not intended to limi t the.invention to the disclosures made herein. Variations and changes which are obviousto one skilled in the art are intended to be within the scope and nature of theinvention as defined in the appended claims.
Claims
CLAIMS I. A compound of the Formula J where a) Rt is-C(O)CH(CH(CH3)2)NH2 or -C(O)CH(CH(CHj)CH2CH3)NH2 and R2 is -C(O)C3-C3, saturated or monounsaturated, optionally substituted alkyl; or 10 b) Rj is -C(O)C3-C2i saturated or monounsaturated, optionally substituted alkyl and R2 is -C{O)CH(CH(CH3)0NH2 or -C(O)CH(CH(CH3)CH2CH5)NH2; and R3 is OH or H; and pharmaceutically acceptable salts thereof.
2. A compound according to claim 1, wherein R (is -C(O)CH(CH(CH3)2)NH2 or -C(O)CH(CH(CH3)CH2CH3)NH3 and R3 is -C(0)CyC21 saturated or monounsaturated, optionally substituted alkyl. 2D3. A compound according to claim 1 wherein the -CAO) alkyl comprises a C? to Ci7, saturated or n:9 monounsaturated, alkyl.
4. A compound according to claim 1 wherein R3 is hydroxy. 25 5. A compound according to claim 1, selected from the group consisting of (R)-9 12 (Stearo; ioxymethyi)-'1 iL-valy3o>y)butyl]guanine ΙΟ (R)-9-[ 2-(My ristoy lox y me thy 1) —4-(L-val ylox v)bu ty I ] g u ani ne. (R)-9-[2-(OieoyIoxYmethy])-4-fL-valy]oxy)buiy]]guamne, (R)-9'[2’(ButyrloxymeLhyl)-4-(L-va]yloxy)buiy]]guanjne, (R)-9-f2-(Dec anoyloxy methyl )-4-(L-v2ly]oxy)buryl)guamne. (R)-9'[2-(DocosanoyIoxyme[hy])-4-{L-va]y]oxy)biJiy]]giianjne, (R)-9~[4-{L-Isoleucy]cixy)-2-(siearoy]oxymeiby])buiy]] guanine, (R)-9-[2-(Decanoyloxymethyl)^-(L-iso]cucy]oxy)buryl]guanine, R)-9-[4-(L-]soleucyloxy)-2-(myristoyloxymeibyl)butylj guanine, (R)-9'[2-(4-Acetylbutyry]oxymethyI-4-(L-valyloxy)butyl] guanine, (R)-9-[2-Docecanoyloxymelhy]-4AL'Va]y}oxy jbutyl] guanine, (R)-9-I2-Pa]mitoy]oxymethyI'4-(L-va!y]oxy)bury]Jguanine, (R)-2-amino-9-(2-Stearoy]oxymethy]-4-(L-valyloxy)buiyl)purine, (2?)-9-[2-(L-Va!yloxymetbyl)-4-(stearoylo*y)butyl]guanine or a pharmaceutically acceptable salt thereof tcaroyloxy methy j)-4-(L-valy loxyjbutyl jgu an inc.
7. (R)-9-[2-(Slearoyloxymethyl)-4-(L-valyJoxy)buty]]guanine or a pharmaceutically acceptable .salt thereof.
8. A pharmaceutical composition comprising a compound according to claim 1 in conjunction with a pharmaceutically acceptable carrier or diluent.
9. A pharmaceutical composition comprising a compound according to claim 5 25 in conjunction with a pharmaceutically acceptable carrier or diluent.1 0. A pharmaceutical composition comprising a compound according to claim 6 in conjunction with a pharmaceutically acceptable carrier or diluent. A use of an effective amount of a compound according to claim 1 in the manufacture of a vital infections in a human or animal12. A use according io claim 11 for the treatment or prophylaxis of herpes infecrions including Varicella zoster virus, Herpes simplex virus types 1 &. 2, Epstein-Barr virus or Herpes type 6 (HHV-6) and type 8 (HHV-8).13 A use according to claim 11 for the treatment or prophylaxis of retroviral infections including SIV, HTV-1 and HIV-2.
14. A method for the preparation of a compound as defined in claim i, the method comprising a) optionally N-protecting the purine 2 and / or 6 positions of a compound of formula I wherein Rj and R2 are each hydrogen; b) regioselectively acylating the compound of Formula 1 at the side chain 4-hydroxy group with either i) an optionally N-protected valine or isoleucine group, ii) an optionally substituted, saturated or monounsaturated C3C;;COOH derivative, or iii) a regioselective protecting group; c) acylating at the side chain 2-hydroxymethyl group with i) an optionally N-protected valine or isoleucine group, or ii) an optionally substituted, saturated or monounsaturated C3CuCOOH derivative; d) replacing the regioselective protecting group at R_b if present, with i) an optionally N-protected valine or isoleucine group; or ii) an optionally substituted, saturated or monounsaturated C3C2|C00H derivative; and e) deprotecting the resulting compound as necessary. -7115. Use of a compound according to claim 1 in preparation of a composition for the treatment or prophylaxis of viral infections in a human or animal.
16. The use according to claim 15 for the treatment or prophylaxis of herpes infections 5 including Varicella zoster virus, Herpes simplex virus types 1 & 2, Epstein-Barr virus or Herpes type 6 (HHV-6) and type 8 (HHV-8).
17. The use according to claim 15 for the treatment or prophylaxis of retroviral infections including SIV, HIV-1 and HIV-2.
18. Compounds according to claim 1, pharmaceutical compositions comprising them and methods of treatment, use and preparation involving them, substantially as hereinbefore described with reference to the examples.
